Liminal BioSciences (LMNL) 6-K 10 Aug 20 Liminal Biosciences Reports Financial Results for Q2-2020 Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Jun. 30, 2020
Cover [Abstract]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Entity Registrant Name	LIMINAL BIOSCIENCES INC.
Entity Central Index Key	0001351172
Current Fiscal Year End Date	--12-31

Consolidated Statements of Fina

Consolidated Statements of Financial Position (Unaudited) - CAD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 25,986	$ 61,285
Accounts receivable (note 4)	4,044	4,086
Income tax receivable	641	9,214
Inventories (note 5)	7,698	7,532
Prepaids	6,510	12,733
Total current assets	44,879	94,850
Other long-term assets	1,180	1,170
Capital assets	20,559	21,471
Right-of-use assets (note 6)	30,138	33,254
Intangible assets	13,816	13,846
Deferred tax assets	507	507
Total assets	111,079	165,098
Current liabilities
Accounts payable and accrued liabilities (note 7)	19,318	22,808
Current portion of lease liabilities (note 8)	8,545	8,290
Current portion of long-term debt (note 9)		165
Total current liabilities	27,863	31,263
Long-term portion of lease liabilities (note 8)	28,708	29,947
Other long-term liabilities (note 10)	201	285
Long-term debt (note 9)	8,785	8,669
Total liabilities	65,557	70,164
EQUITY
Share capital (note 11a)	943,955	932,951
Contributed surplus (note 11b)	38,529	43,532
Warrants (note 11c)	95,856	95,856
Accumulated other comprehensive loss	(3,031)	(3,099)
Deficit	(1,022,163)	(967,051)
Equity attributable to owners of the parent	53,146	102,189
Non-controlling interests	(7,624)	(7,255)
Total equity	45,522	94,934
Total liabilities and equity	$ 111,079	$ 165,098

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - CAD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Revenues (note 12)	$ 540	$ 762	$ 1,643	$ 3,026
Expenses
Cost of sales and other production expenses (note 5)	458	592	1,142	1,722
Research and development expenses	15,797	22,289	32,782	39,760
Administration, selling and marketing expenses	9,851	18,045	20,523	25,140
Loss (gain) on foreign exchange	539	256	(593)	(1,520)
Finance costs	1,852	3,348	3,482	10,497
Loss (gain) on extinguishments of liabilities (note 9,11a)		92,294	(79)	92,374
Change in fair value of financial instruments measured at fair value through profit or loss		(1,369)		(1,140)
Net loss from continuing operations before taxes	(27,957)	(134,693)	(55,614)	(163,807)
Income tax expense (recovery) from continuing operations:
Current	(141)	1,239	(141)	1,239
Total income tax expense (recovery) from continuing operations	(141)	1,239	(141)	1,239
Net loss from continuing operations	(27,816)	(135,932)	(55,473)	(165,046)
Net income from discontinued operations, net of taxes of $nil (note 3)		2,229		2,509
Net loss	(27,816)	(133,703)	(55,473)	(162,537)
Net income (loss) attributable to:
Non-controlling interests - continuing operations	(56)	(86)	(369)	(784)
Owners of the parent
-Continuing operations	(27,760)	(135,846)	(55,104)	(164,262)
-Discontinued operations		2,229		2,509
Total Net loss attributable to owners of the parent from continuing and discontinued operations	(27,760)	(133,617)	(55,104)	(161,753)
Net loss	$ (27,816)	$ (133,703)	$ (55,473)	$ (162,537)
Income (loss) per share attributable to the owners of the parent basic and diluted:
From continuing operations	$ (1.19)	$ (8.26)	$ (2.35)	$ (18.90)
From discontinued operations		0.14		0.29
Income (loss) per share attributable to the owners of the parent basic and diluted	$ (1.19)	$ (8.12)	$ (2.35)	$ (18.61)
Weighted average number of outstanding shares (in thousands)	23,420	16,451	23,403	8,692

Consolidated Statements of Op_2

Consolidated Statements of Operations (Unaudited) (Parenthetical) - CAD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Income Statement [Abstract]
Net income from discontinued operations, net of taxes	$ 0	$ 0

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - CAD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Statement Of Comprehensive Income [Abstract]
Net Loss	$ (27,816)	$ (133,703)	$ (55,473)	$ (162,537)
Items that may be subsequently reclassified to profit and loss:
Exchange differences on translation of foreign operations from continuing operations	(12)	775	68	780
Exchange differences on translation of foreign operations from discontinued operations (note 3)		(1,940)		(1,868)
Other comprehensive income (loss)	(12)	(1,165)	68	(1,088)
Comprehensive loss	(27,828)	(134,868)	(55,405)	(163,625)
Comprehensive income (loss) attributable to:
Non-controlling interests - continuing operations	(56)	(86)	(369)	(784)
Owners of the parent
Owners of the parent- Continuing operations	(27,772)	(135,071)	(55,036)	(163,482)
Owners of the parent- Discontinued operations		289		641
Comprehensive income, attributable to owners of parent	(27,772)	(134,782)	(55,036)	(162,841)
Comprehensive loss	$ (27,828)	$ (134,868)	$ (55,405)	$ (163,625)

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - CAD ($) $ in Thousands	Total	Share Capital	Contributed Surplus	Warrants	Foreign Currency Translation Reserve	Deficit	Total Equity (Deficiency) Attributable to Owners of the Parent	Non-controlling Interests
Beginning balance at Dec. 31, 2018	$ (63,146)	$ 583,117	$ 21,923	$ 95,296	$ (1,252)	$ (755,688)	$ (56,604)	$ (6,542)
Net Loss	(162,537)					(161,753)	(161,753)	(784)
Foreign currency translation reserve	(1,088)				(1,088)		(1,088)
Issuance of shares	349,834	349,834					349,834
Share-based payments expense (note 11b)	16,429		16,429				16,429
Share-based compensation paid in cash (note 11b)	(421)		(421)				(421)
Share issuance cost	(5,321)					(5,321)	(5,321)
Issuance of warrants (note 11c)	560			560			560
Effect funding arrangements on non-controlling interests						(176)	(176)	176
Ending balance at Jun. 30, 2019	134,310	932,951	37,931	95,856	(2,340)	(922,938)	141,460	(7,150)
Beginning balance at Dec. 31, 2019	94,934	932,951	43,532	95,856	(3,099)	(967,051)	102,189	(7,255)
Net Loss	(55,473)					(55,104)	(55,104)	(369)
Foreign currency translation reserve	68				68		68
Issuance of shares	1,240	1,240					1,240
Share-based payments expense (note 11b)	4,801		4,801				4,801
Share-based compensation paid in cash (note 11b)	(40)		(40)				(40)
Shares issued pursuant to a restricted share unit plan (note 11b)		9,764	(9,764)
Share issuance cost	(8)					(8)	(8)
Ending balance at Jun. 30, 2020	$ 45,522	$ 943,955	$ 38,529	$ 95,856	$ (3,031)	$ (1,022,163)	$ 53,146	$ (7,624)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - CAD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows used in operating activities
Net loss from continuing operations for the period	$ (55,473)	$ (165,046)
Net income from discontinued operations for the period		2,509
Adjustments to reconcile net loss to cash flows used in operating activities:
Finance costs and foreign exchange	2,805	9,105
Carrying value of capital and intangible assets disposed	83	190
Change in fair value of financial instruments measured at fair value through profit or loss		(1,140)
Loss (gain) on extinguishments of liabilities (note 9,11a)	(79)	92,374
Share-based payments expense (note 11b)	4,761	16,008
Depreciation of capital assets	1,314	1,880
Depreciation of right-of-use assets (note 6)	2,264	2,422
Amortization of intangible assets	494	630
Cash flows from (used in) operations before changes in working capital	(43,831)	(41,068)
Change in non-cash working capital items	11,894	(5,565)
Cash flows used in operating activities	(31,937)	(46,633)
Cash flows from (used in) financing activities
Proceeds from share issuances (note 11a)		118,785
Proceeds from debt and warrant issuances		19,859
Repayment of principal on long-term debt	(165)	(576)
Repayment of interest on long-term debt	(503)	(3,032)
Payments of principal on lease liabilities (note 8)	(3,066)	(3,541)
Payment of interest on lease liabilities (note 8)	(853)	(1,180)
Debt, share and warrants issuance costs	(8)	(6,581)
Cash flows from financing activities	(4,595)	123,734
Cash flows used in investing activities
Additions to capital assets	(370)	(2,690)
Additions to intangible assets	(499)	(842)
Residual proceeds from sale of discontinued operations business (note 3)	1,175
Transaction costs paid relating to the sale of discontinued operations business (note 3)	(787)
Interest received	283	153
Cash flows used in investing activities	(198)	(3,379)
Net change in cash and cash equivalents during the period	(36,730)	73,722
Net effect of currency exchange rate on cash and cash equivalents	1,431	(109)
Cash and cash equivalents, beginning of period	61,285	7,389
Cash and cash equivalents, end of period	25,986	81,002
Comprising of:
Cash	21,806	81,002
Cash equivalents	4,180
Cash and cash equivalents, end of period	$ 25,986	$ 81,002

Nature of operations and going

Nature of operations and going concern	6 Months Ended
	Jun. 30, 2020
Disclosure Of Nature Of Operations And Going Concern [Abstract]
Nature of operations and going concern	1. Nature of operations and going concern Liminal BioSciences Inc. or Liminal, or the Company is incorporated under the Canada Business Corporations Act and is a publicly traded clinical-stage biopharmaceutical company (Nasdaq symbol: LMNL) focused on discovering, developing and commercializing novel treatments for patients suffering from diseases that have high unmet medical needs Liminal’s lead small molecule segment product candidate, fezagepras (PBI-4050), is currently being developed for multiple fibrotic diseases. The plasma‑derived therapeutics segment leverages Liminal’s experience in bioseparation technologies used to isolate and purify biopharmaceuticals from human plasma. With respect to this second platform, the Company is focused on the development of its plasma-derived product candidate Ryplazim® (plasminogen) or Ryplazim ® On November 25, 2019 the Company sold the majority of its bioseparations business to a third party. These activities are presented as discontinued operations in the consolidated financial statements. Details on this transaction and the results from discontinued operations are disclosed in note 3. The Company’s head office is located at 440, Boul. Armand-Frappier, suite 300, Laval, Québec, Canada, H7V 4B4. Liminal has business operations in Canada, the United Kingdom and the United States. The Company’s shares were trading on both the Nasdaq and TSX up until August 5, 2020 and subsequently are solely traded on Nasdaq following the voluntary delisting by the Company from the TSX. Structured Alpha LP or SALP is Liminal’s majority and controlling shareholder and is considered Liminal’s parent entity for accounting purposes. Thomvest Asset Management Ltd. is the general partner of SALP and the ultimate controlling parent, for accounting purposes, of Liminal is The 2003 TIL Settlement. The unaudited condensed interim consolidated financial statements for the quarter and six months ended June 30, 2020 have been prepared in accordance with International Financial Reporting Standards or IFRS as issued by the International Accounting Standards Board or IASB on a going concern basis, which presumes the Company will continue its operations for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the ordinary course of business. During the six months ended June 30, 2020, the Company incurred a net loss of $55.5 million ($162.5 million for the six months ended June 30, 2019 including an extinguishment of liabilities of $92.4 million) and had negative operating cash flows of $31.9 million ($46.6 million for the six months ended June 30, 2019). In addition, at June 30, 2020, the Company had a working capital of $17.0 million ($63.6 million at December 31, 2019) and an accumulated deficit of $1,022.2 million ($967.1 million at December 31, 2019). Given Liminal's main activities continue to be in the R&D stage, management has concluded it will need additional sources of financing to ensure it has sufficient funds to continue its operations for at least the next twelve months. Until the Company completes a significant financing, it continues operating at a low spending level, pacing investments on new research programs, and reducing infrastructure cost, where possible. The need to complete multiple financing transactions is likely to continue until the Company can generate sufficient product revenues to finance its cash requirements. Meanwhile, management expects to finance future cash needs primarily through a combination of public or private equity offerings, debt financings, strategic collaborations, business and asset divestitures, and grant funding. Despite the Company’s efforts to obtain the necessary funding and improve profitability of its operations, there can be no assurance of its success in doing so, especially with respect to its access to further funding on acceptable terms, if at all, particularly if the COVID-19 pandemic continues to disrupt global financial markets. These circumstances indicate the existence of a material uncertainty that may cast significant doubt about the Company’s ability to continue as a going concern. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays in the Company’s preclinical, clinical and regulatory efforts, which are critical to the realization of its business plan. These unaudited condensed interim consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.

Significant accounting policies

Significant accounting policies	6 Months Ended
	Jun. 30, 2020
Significant Accounting Policies [Abstract]
Significant accounting policies	2. Significant accounting policies a) Accounting framework These unaudited condensed interim consolidated financial statements or interim financial statements for the quarter and six months ended June 30, 2020 have been prepared in accordance with IAS 34, Interim financial reporting www.sec.gov/edgar and at www.sedar.com These interim financial statements were approved for issue on August 10, 2020 by the Company’s Audit, Risk and Finance committee as delegated by the Board of Directors. b) Adoption of new accounting standards The accounting policies used in these interim financial statements are consistent with those applied by the Company in its December 31, 2019 audited annual consolidated financial statements and no new accounting standards were adopted during the six-months ended June 30, 2020. c) New standards and interpretations not yet adopted The IFRS accounting standards, amendments, and interpretations that the Company reasonably expects may have a material impact on the disclosures, the financial position or results of operations of the Company when applied at a future date are as follows: Amendments to IAS 1, Presentation of Financial Statements , - IAS 1 has been revised to clarify how to classify debt and other liabilities as current or non-current. The amendments help to determine whether, in the statement of financial position, debt and other liabilities with an uncertain settlement date should be classified as current (due or potentially due to be settled within one year) or non-current. The amendments also include clarifying the classification requirements for debt an entity might settle by converting it into equity. The amendment becomes effective for annual reporting periods beginning on or after January 1, 2022 and earlier application is permitted. The Company is currently evaluating the impact of adopting this amendment on its consolidated financial statements. Amendment to IFRS 16 Leases or IFRS 16 has been revised to incorporate an amendment issued by the IASB in May 2020. The amendment permits lessees not to assess whether particular COVID-19-related rent concessions are lease modifications and, instead, account for those rent concessions as if they were not lease modifications. In addition, the amendment to IFRS 16 provides specific disclosure requirements regarding COVID-19-related rent concessions. The amendment becomes effective for annual reporting periods beginning on or after June 1, 2020 and earlier application is permitted. Presently, the Company has not benefited from COVID-19 related rent concessions. d) Significant accounting judgements and critical accounting estimates The preparation of the interim consolidated financial statements requires the use of judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the accompanying disclosures. The uncertainty that is often inherent in these estimates and assumptions could result in material adjustments to assets or liabilities affected in future periods. Other than as described below, the significant accounting judgments and critical accounting estimates applied by the Company, disclosed in the consolidated financial statements for the year ended December 31, 2019, remain unchanged. COVID-19 – The negative impact of the COVID-19 pandemic on the financial statements for the quarter and six months ended June 30, 2020 has been limited, however the Company is eligible to a Government of Canada salary subsidy program which it was able to claim during the second quarter of 2020 and which may provide further financial support while the program is available. Consistent within the global biopharmaceutical sector, some clinical programs may have been impacted by the shift of resources within hospitals to COVID-19 and related matters, resulting in potential delays to recruitment or site initiation on our clinical and preclinical programs, and potentially causing an adjustment of certain development timelines and activities. The partial disruption caused by COVID-19 may continue to impact the Company’s operations, workforce and overall business by delaying the progress of our research and development programs, regulatory submissions and reviews, regulatory inspections, production and plasma collection activities and business and corporate development activities. There is uncertainty as to the duration of the COVID-19 pandemic and related government restrictions, including travel bans, the impact on our workforce, and the availability of donors, health subjects and patients for the conduct of clinical trials, and the effects of the COVID-19 pandemic, including on the global economy, continue to be fluid. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these interim financial statements, the Company is not aware of any specific event or circumstance that would require it to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities, and the Company is unable to estimate the potential impact on its future business or our financial results as of the date of this filing. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Share-based compensation – To determine the fair value of stock options on a given date, the Company must determine the assumptions that will be used as inputs to the Black-Scholes option pricing model, including the assumption regarding the future volatility of the common shares of Liminal for the expected life of the stock options. The Company uses the historical volatility as a starting basis for the estimate and also considers whether there are factors that would indicate that the past volatility is not indicative of the future volatility. In making this assessment, management considers changes in Liminal’s activities and other factors such as a significant share consolidation. As the volatility is an assumption that has a significant impact on the calculated value of a stock option, the impact of this estimate can significantly impact the share-based payment expense over the vesting period of an award. On March 23, 2020, the board of directors of the Company approved a plan to seek shareholder approval to modify the exercise price of certain stock options as disclosed in note 11b. In order to determine when the expense related to this modification is recognized in the consolidated statement of operations, management evaluated the timing of notification to option holders, the timing and method of determining the exercise price and the service period. Management further considered whether the holders of the stock options had sufficient understanding of the terms and conditions of the potentially revised awards, the degree of certainty of the approval for the repricing and whether the service period for earning the rights to the awards had commenced. Management concluded that the definition of the grant date was not met but that the service period had commenced and therefore a preliminary calculation of the incremental fair value of the repricing of the awards was performed using assumptions as of March 31, 2020. On May 26, 2020, the conditions for a grant date were met and the options exercise price was revised to $15.21 and a final calculation to determine the incremental fair value of the repriced options was performed.

Discontinued operations

Discontinued operations	6 Months Ended
	Jun. 30, 2020
Discontinued Operations [Abstract]
Discontinued operations	3. Discontinued operations On November 25, 2019, the Company sold two subsidiaries in its bioseparations segment, representing the majority of its bioseparations operations and all of the bioseparations revenues. The comparative periods results and cash flows of the business sold have been presented as discontinued operations with the revenues and costs relating to ceased activities being reclassified and presented retrospectively in the consolidated statements of operations, statements of comprehensive loss and notes to the interim financial statements as discontinued operations. Results and cash flows from discontinued operations The results from discontinued operations for the quarter and six months ended June 30, 2019 are as follows: Quarter ended Six months ended June 30, 2019 June 30, 2019 Revenues $ 7,990 $ 13,959 Expenses Cost of sales and other production expenses 3,289 6,511 Research and development expenses 1,868 3,589 Administration, selling and marketing expenses 545 1,094 Gain on foreign exchange (149 ) (156 ) Finance costs 208 412 Net income from discontinued operations, net of tax of $nil $ 2,229 $ 2,509 The cash flows from discontinued operations for the six months ended June 30, 2020 and 2019 are presented in the following table: June 30, June 30, Six months ended 2020 2019 Cash flows from in operating activities $ - $ 1,056 Cash flows used in financing activities - (460 ) Cash flows from (used) in investing activities 388 (486 ) Net change in cash during the quarter $ 388 $ 110 Net effect of currency exchange rate on cash - (44 ) Net increase in cash generated by discontinued operations $ 388 $ 66

Accounts receivable

Accounts receivable	6 Months Ended
	Jun. 30, 2020
Trade And Other Receivables [Abstract]
Accounts receivable	4. Accounts receivable June 30, December 31, 2020 2019 Trade receivables $ 375 $ 44 Tax credits and government grants receivable 2,786 1,546 Sales taxes receivable 463 863 Other receivables 420 1,633 $ 4,044 $ 4,086

Inventories

Inventories	6 Months Ended
	Jun. 30, 2020
Classes Of Inventories [Abstract]
Inventories	5. Inventories June 30, December 31, 2020 2019 Raw materials $ 7,442 $ 7,175 Finished goods 256 357 $ 7,698 $ 7,532 Inventories sold from continuing operations in the amount of $266 and $630 for the quarter and six months ended June 30, 2020 ($457 and $1,486 for the quarter and six months ended June 30, 2019) were recognized as cost of sales and other production expenses while discontinued operations were $nil for the six months ended June 30, 2020 ($3,394 and $5,720 for the quarter and six months ended June 30, 2019). Inventory write‑downs in continuing operations were $175 and $327 for the quarter and six months ended June 30, 2020 ($nil for the six months ended June 30, 2019) and from discontinued operations were $nil for the six months ended June 30, 2020 ($53 and $467 from the quarter and six months ended June 30, 2019), also included in cost of sales and other production expenses, were recorded.

Right-of-use assets

Right-of-use assets	6 Months Ended
	Jun. 30, 2020
Disclosure Of Quantitative Information About Rightofuse Assets [Abstract]
Right-of-use assets	6. Right-of-use assets Production and laboratory Buildings equipment Other Total Net book value as at January 1, 2020 $ 32,246 $ 912 $ 96 $ 33,254 Lease modifications and other remeasurements (932 ) - - (932 ) Depreciation expense (1,938 ) (296 ) (30 ) (2,264 ) Effect of foreign exchange differences 80 - - 80 Net book value at June 30, 2020 $ 29,456 $ 616 $ 66 $ 30,138

Accounts payable and accrued li

Accounts payable and accrued liabilities	6 Months Ended
	Jun. 30, 2020
Trade And Other Current Payables [Abstract]
Accounts payable and accrued liabilities	7. Accounts payable and accrued liabilities June 30, 2020 December 31, 2019 Trade payables $ 8,609 $ 10,496 Wages and benefits payable 4,906 5,593 Current portion of royalty payment obligations (note 10) 3,308 3,043 Current portion of license acquisition payment obligation - 1,302 Current portion of other employee benefit liabilities (note 10) 2,495 2,374 $ 19,318 $ 22,808 During the quarter ended June 30, 2020 the Company recorded an out-of-period adjustment of $819 relating to December 31, 2019 which has resulted in a decrease in R&D expenses and trade payables.

Lease liabilities

Lease liabilities	6 Months Ended
	Jun. 30, 2020
Lease Liabilities [Abstract]
Lease liabilities	8. Lease liabilities The transactions affecting the lease liabilities during the six months ended June 30, 2020 were as follows: Balance at January 1, 2020 $ 38,237 Interest expense 3,153 Payments (3,919 ) Lease modification and other remeasurements (1,068 ) Effect of foreign exchange differences 850 Balance at June 30, 2020 $ 37,253 Less current portion of lease liabilities 8,545 Long-term portion of lease liabilities $ 28,708 Interest expense on lease liabilities for the quarter and six months ended June 30, 2020 was $1,604 and $3,153 ($1,851 and 3,639 for the quarter and six months ended June 30, 2019) and is included as part of finance costs in the consolidated statement of operations.

Long-term debt

Long-term debt	6 Months Ended
	Jun. 30, 2020
Disclosure Of Detailed Information About Borrowings [Abstract]
Long-term debt	9. Long-term debt The transactions during the six months ended June 30, 2020 were as follows: 2020 Balance at January 1 $ 8,834 Stated and accreted interest 619 Repayment of principal (165 ) Repayment of stated interest (503 ) Balance at June 30 $ 8,785 At June 30, 2020 and December 31, 2019, the carrying amount of the long-term debt relates to our outstanding loan with SALP or Loan with the parent, which has a principal of $10,000 maturing on April 23, 2024, bears an annual interest rate of 10.0% payable quarterly and an effective interest rate of 15,05%. The Loan with the parent is secured by all the assets of the Company and requires that certain covenants be respected including maintaining an adjusted working capital ratio. 2019 On February 22, 2019, the Company amended the fourth loan agreement or Credit Facility with the addition of two tranches of US$10 million and US$5 million which the Company drew on February 22 and March 22, 2019, respectively. Those two tranches bear interest at an annual rate of 8.5% payable quarterly. Concurrently with the amendment, the Company agreed to reduce the exercise price of Warrants #9 from $1,000.00 to $156.36 per preferred share and to immediately issue those warrants (note 12). The incremental fair value of the warrant liability of $1,137 due to this change was recognized as deferred financing fees related to the additional two tranches received. The Company recorded the credit facility draws on February 22, 2019 and March 22, 2019 at its fair value at the transaction date less the associated transaction costs and financing fees of $45 and $1,137 respectively, for a net amount of $18,677. On April 23, 2019, the Company entered into a debt restructuring agreement with the long-term debt holder whereby the entirety of the principal on the Credit Facility plus a portion of the interest due, the entirety of the First and Second Original Issue Discount or OID loans and the majority of the Third OID loan would be repaid by Liminal by the issuance of common shares, at a conversion price, rounded to the nearest two decimals, of $15.21 per common share. Consequently, the US$95 million of principal plus interest due on the Credit Facility was reduced to $663 and the aggregate face value of the three OID loans was reduced by $99,552 to $10,000 with the remaining balance of the Third OID loan modified into an interest-bearing loan at a stated interest rate of 10% payable quarterly, referred to as the Loan with the parent. This resulted in the reduction of the long-term debt recorded on the consolidated statement of financial position by $141,536. The Company issued 15,050,312 common shares on that date which were recorded in share capital at a value of $228,915. The difference between the carrying amount of the debt converted into common shares and the increase in the value of the share capital is recognized as a loss on extinguishment of a loan of $87,379. The balance of interest due on the credit facility of $663 was paid in cash. Pursuant to the debt restructuring, the Company cancelled the warrants previously held by SALP and replaced them with new warrants having an exercise price rounded to the nearest two decimals of $15.21 per common share, expiring on April 23, 2027 (note 11c). The incremental fair value of the replacement warrants was recognized in warrants equity and as part of the loss on the debt extinguishment together with the legal fees incurred to finalize all the related legal agreements. The modification in terms of the remaining balance of the Third OID loan of $10,000 was accounted for as an extinguishment of the long-term debt and the re-issuance of a new interest-bearing loan. The difference between the carrying amount of the loan extinguished of $4,667 and the fair value of the new Loan with the parent of $8,521 recognized was recorded as a loss on debt extinguishment of $3,854. The fair value of the modified loan was determined using a discounted cash flow model with a market interest rate of 15.1%. As a result of this transaction and the extinguishments of debt that occurred earlier in the year following payments made to suppliers by the issuance of equity (note 11a), the consolidated statement of operations for the quarter and the six months ended June 30, 2020, includes a loss on extinguishment of liabilities of $92,374 detailed as follows: Loss on extinguishment of liabilities due to April 23, 2019 loan modification Comprising the following elements: Debt to equity conversion $ 87,379 Expensing of financing fees on loan extinguishment 653 Extinguishment of previous loan (4,667 ) Recognition of modified loan 8,521 Expensing of increase in the fair value of the warrants 408 Loss on extinguishment of liabilities due to April 23, 2019 loan modification $ 92,294 Loss on extinguishment of liabilities to suppliers 80 Loss on extinguishments of liabilities $ 92,374

Other long-term liabilities

Other long-term liabilities	6 Months Ended
	Jun. 30, 2020
Miscellaneous Noncurrent Liabilities [Abstract]
Other long-term liabilities	10. Other long-term liabilities June 30, December 31, 2020 2019 Royalty payment obligations $ 3,423 $ 3,148 Other employee benefit liabilities 2,581 2,554 $ 6,004 $ 5,702 Less: Current portion of royalty payment obligations (note 7) (3,308 ) (3,043 ) Current portion of other employee benefit liabilities (note 7) (2,495 ) (2,374 ) $ 201 $ 285

Share capital and other equity

Share capital and other equity instruments	6 Months Ended
	Jun. 30, 2020
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]
Share capital and other equity instruments	11. Share capital and other equity instruments a) Share capital Changes in the issued and outstanding common shares of the Company during the six months ended June 30, 2020 and 2019 were as follows: June 30, 2020 June 30, 2019 Number Amount Number Amount Balance - beginning of period 23,313,164 $ 932,951 720,306 $ 583,117 Issued to acquire assets 96,833 1,240 4,420 1,326 Shares issued pursuant to a restricted share units plan (note 11b) 10,355 9,764 - - Shares issued pursuant to debt restructuring 15,050,312 228,915 Shares issued for cash - - 7,536,654 118,648 Shares released from escrow - - - 400 Shares issued in payment to suppliers - - 1,472 545 Balance - end of period 23,420,352 $ 943,955 23,313,164 $ 932,951 2020 On January 29, 2020, the Company issued 96,833 common shares as a consideration for the final payment for the licence acquired on January 29, 2018. This transaction was accounted for as an extinguishment of the license acquisition payment obligation and the difference between the carrying value of the liability of $1,319 and the amount recorded for the shares issued of $1,240, which were valued at the market price of the shares on their date of issuance, was recorded as a gain on extinguishment of liabilities of $79 during the quarter ended March 31, 2020. 2019 In November 2018, the Company entered into an At-the-Market or ATM Equity Distribution Agreement or EDA under which the Company is able, at its discretion and from time to time, subject to conditions in the EDA, to offer common shares through ATM issuances on the TSX or any other marketplace for aggregate proceeds not exceeding $31 million. This agreement provides that common shares are to be sold at market prices prevailing at the time of sale. The Company issued a total of 12,865 common shares at an average price of $327.55 per share under the ATM in January and February 2019, for aggregate gross proceeds of $4,214, less transaction costs of $248 recorded in deficit, for total net proceeds of $3,966. The use of the ATM facility was suspended concurrently with our Nasdaq registration. On January 29, 2019, the Company issued 4,420 common shares in settlement of second payment due for the licence acquired on January 29, 2018 and recorded $1,326 in share capital based on the market value of the shares on that date. On February 25 and 27, 2019, the Company issued a total of 1,472 common shares in payment for amounts due to certain suppliers. This transaction was accounted for as an extinguishment of liabilities and the difference between the carrying value of the accounts payable of $465 and the amount recorded for the shares issued of $545, which were valued at the market price of the shares on their date of issuance, was recorded as a loss on extinguishment of liabilities of $80. As part of the settlement agreement concluded in April 2019 with the former CEO of the Company, common shares held in escrow as security for a share purchase loan of $400 to the former CEO were released and the loan extinguished in exchange for the receipt of a payment of $137, representing the fair value of the shares at the time of the settlement. On April 23, 2019, the Company issued 15,050,312 common shares as part of the debt restructuring (note 9). The shares issued in relation with the debt restructuring contained trading restrictions and accordingly, the Company determined that their quoted price did not fairly represent the value of the shares issued. As such, the issued shares were recorded at fair value using a market approach under a level 2 fair value measurement of $15.21 per share, resulting in a value of the shares issued of $228,915. The fair value was based on a share issuance for cash on the same date with a non-related party. The difference between the adjustment to the carrying value of the loan of $141,536 and the amount recorded for the shares issued of $228,915 was recorded as a loss on extinguishment of a loan of $87,379. Concurrently, the Company closed two private placements for 4,931,161 common shares at a subscription price rounded to the nearest five decimals of $15.21 for gross proceeds of $75,000, less transaction costs of $4,802 recorded in deficit, for total net proceeds of $70,197. In June 2019, the Company completed the rights offering or Rights Offering for the holders of its common shares at the close of business on May 21, 2019 who elected to exercise their rights under the Rights Offering allowing them to subscribe for up to 20 common shares for a subscription price rounded to the nearest five decimals of $15.21 per common share. The Company issued 2,592,628 common shares for gross proceeds of $39,434 as part of the Right Offerings less transactions costs of $271 recorded in deficit, for total net proceeds of $39,163. b) Contributed surplus (Share-based payments) Stock options Changes in the number of stock options outstanding during the six months ended June 30, 2020 and 2019 were as follows: June 30, 2020 June 30, 2019 Weighted Weighted average average Number exercise price Number exercise price Balance - beginning of period 2,209,864 $ 38.72 21,625 $ 1,464.49 Granted 436,570 14.06 2,047,560 35.10 Forfeited (64,141 ) 24.42 (1,429 ) 1,352.79 Cancelled - - (9,094 ) 1,164.74 Expired (1,435 ) 2,433.20 (1,902 ) 1,110.29 Repriced - options before repricing (1,929,685 ) 35.14 - - Repriced - options after repricing 1,929,685 15.21 - - Balance - end of period 2,580,858 $ 18.67 2,056,760 $ 43.23 2020 In March 2020, Liminal’s board of directors approved a plan to reduce the exercise price of the stock options issued in June 2019, held by active employees and directors at the time of the repricing. On May 26, 2020, a revised exercise price, pending approval, of $15.21 was determined, changing the exercise price to the higher of (i) $15.21 and (ii) the five-day weighted average share price of Liminal common shares on the repricing date. On June 8, 2020, the repricing of 1,929,685 of the outstanding stock options having exercise prices of $27.00 and $36.00 to the revised exercise price was approved at the Company’s annual shareholder meeting. Although the stock options were not repriced until May 26 2020, management concluded that the service period for employees and directors to earn the modified awards had commenced from the date the Company informed the holders of these stock options of the repricing proposal and the expense resulting from the repricing plan should be recognized starting from that date. Using the revised exercise price of $15.21, the Company calculated the final incremental fair value of the repricing on the grant date of May 26, 2020 to be $3,000. This incremental fair-value will be amortized from the services commencement date of March 25 over the remaining vesting period of the repriced options. The incremental grant date fair value of the repriced options was estimated based on the Black-Scholes option-pricing model calculated before and after the effect of the repricing. The following Black-Scholes assumption were used: Expected dividend rate - Expected volatility of share price 93.2 % Risk-free interest rate 0.4 % Expected life in years 6.3 Weighted average grant date incremental fair value $ 1.55 In June 2020, 436,570 stock options, having an exercise price of $14.06 and vesting over a period of up to four years, were issued to employees and directors. All stock options granted in 2019 and 2020 have a contractual life of 10 years. 2019 In January 2019, 1,622 stock options were granted at an exercise price of $300.00 and vesting on December 31, 2019. On June 4, 2019, 1,794,224 stock options were granted to key management at a strike price of $36.00 of which 248,825 stock options vested immediately and the remaining vest over a period up to six years. On June 19, 2019, 251,714 stock options were issued at a strike price of $27.00 of which 60,717 stock options vested immediately and the remaining vest over a period up to four years. The weighted average grant date fair value of the stock options issued in 2019 was $13.17. On June 19, 2019, the Company cancelled the options that were issued prior to June 2019, as the exercise price of these options were so above the market price at the time, that it was highly unlikely that they would ever be exercised. In compensation for their agreement to the cancellation, key management and employees, received the new options granted to them in June 2019 discussed above. Consequently, 9,094 stock options with a weighted average exercise price of $1,164.74 were cancelled. The Company uses the Black-Scholes option pricing model to calculate the fair value of stock options. The weighted average inputs into the model and the resulting grant date fair values during the six months ended June 30, 2020 and 2019, except for the effect of the repricing were as follows: June 30, June 30, 2020 2019 Expected dividend rate - - Expected volatility of share price 91.7 % 45.0 % Risk-free interest rate 0.5 % 1.4 % Expected life in years 6.8 7.3 Weighted average grant date fair value $ 10.51 $ 13.43 At June 30, 2020, options issued and outstanding by range of exercise price are as follows: Weighted average remaining Weighted Weighted Range of Number contractual life average Number average exercise price outstanding (in years) exercise price exercisable exercise price $7.86-$11.99 171,250 9.3 $ 9.58 - $ - $14.06 436,570 9.9 14.06 - - $15.21 1,914,976 8.9 15.21 431,605 15.21 $27.00 - $3,190.00 58,062 8.6 194.23 56,741 185.78 2,580,858 9.1 $ 18.67 488,346 $ 35.03 A share-based payment compensation expense of $2,407 and $4,770 was recorded for the options for the quarter and the six months ended June 30, 2020, respectively ($6,736 and $7,224 for the quarter and the six months ended June 30, 2019). Restricted share units Changes in the number of restricted share units or RSU outstanding during the six months ended June 30, 2020 and 2019 were as follows: June 30, June 30, 2020 2019 Balance - beginning of period 17,565 18,299 Granted - 12,564 Forfeited (24 ) (359 ) Released (10,355 ) - Paid in cash (2,948 ) (8,246 ) Cancelled - (4,249 ) Balance - end of period 4,238 18,009 2020 During the first quarter of 2020, 2,948 RSU were paid in cash resulting in a reduction to contributed surplus of $40. June 30, 2020, 70 vested RSU and 4,168 unvested RSU were outstanding. Share-based payment compensation expense of $17 and $31 was recorded during the quarter and the six months ended June 30, 2020. 2019 On January 31, 2019, the Company granted 12,564 RSU at a grant price of $300.00 and a one-year vesting period. On May 30, 2019, the Company decided to vest the 12,564 RSU and the employees were given the choice to receive the then current value of the shares in cash or to receive the shares at a later date. As a result, 8,246 RSU were released and paid in cash resulting in a reduction to contributed surplus of $421. On May 7, 2019 the 12,886 performance-based RSU pertaining to the “2017-2019” cycle and the “2018-2020” cycle were modified by removing the performance conditions and converting them into time-vesting RSU. The quantity modified into time-vesting units was equivalent to the 100% achievement range whereby in the past, the outcome of the performance conditions could go from zero to 150%. In the past, the Company has always reported the quantity of RSU outstanding as the maximum number of shares that could be issued under the plan. This change resulted in the cancellation of 4,305 units. At June 30, 2019, 7,643 vested RSU and 10,366 unvested RSU were outstanding. Share-based payment compensation expense of $8,161 and $9,205 was recorded during the quarter and the six months ended June 30, 2019. The portion of this compensation related to key management personnel (as defined by IAS 24 Related Party Disclosures) is $5,668 and $6,502 for the quarter and the six months ended June 30, 2019. Share-based payments expense The total share-based payments expense, comprising the above-mentioned expenses for stock options and RSU, has been included in the consolidated statements of operations for the quarters and six months ended June 30, 2020 and 2019 as indicated in the following table: Quarter ended June 30, Six months ended June 30, 2020 2019 2020 2019 Cost of sales and other production expenses $ 10 $ 88 $ 17 $ 88 Research and development expenses 1,068 5,080 2,083 5,772 Administration, selling and marketing expenses 1,346 9,729 2,701 10,569 $ 2,424 $ 14,897 $ 4,801 $ 16,429 Warrants The following table summarizes the changes in the number of warrants outstanding during the six months ended June 30, 2020 and 2019: June 30, 2020 June 30, 2019 Weighted Weighted average average Number exercise price Number exercise price Balance of warrants - beginning of period 172,735 $ 84.33 153,611 $ 1,028.35 Issued to acquire assets - - 19,402 156.36 Cancelled - loan modification - - (168,735 ) 872.51 Issued - loan modification - - 168,735 15.21 Balance of warrants - end of period 172,735 $ 84.33 173,013 $ 94.46 Balance of warrants exercisable - end of period 172,735 $ 84.33 171,013 $ 60.48 On February 22, 2019, pursuant to modifying its fourth loan agreement with SALP, the Company issued 19,402 warrants, referred to as Warrants #9, having an exercise price of $156.36. Warrants #9 do not meet the definition of an equity instrument since the underlying preferred shares qualify as a liability instrument, and therefore they must be accounted for as a financial instrument carried at fair value through profit or loss, presented on our statement of financial position as a warrant liability. During the quarter ended June 30, 2019, the Company recorded an expense of $229 due to the change in fair value of the warrant liability. These warrants were subsequently cancelled in April 2019. As at June 30, 2020, the following warrants were outstanding: Number Expiry date Exercise price 4,000 January 2023 3,000.00 168,735 April 2027 15.21 172,735 $ 84.33

Revenues from continuing operat

Revenues from continuing operations	6 Months Ended
	Jun. 30, 2020
Revenue [Abstract]
Revenues from continuing operations	12. Revenues from continuing operations Quarters ended June 30, Six months ended June 30, 2020 2019 2020 2019 Revenues from the sale of goods $ 504 $ 728 $ 1,405 $ 2,926 Other revenues 36 34 238 100 $ 540 $ 762 $ 1,643 $ 3,026

Government Grants

Government Grants	6 Months Ended
	Jun. 30, 2020
Disclosure Of Government Grants [Abstract]
Government Grants	13. Government Grants For the quarter and six months ended June 30, 2020, the Company recognized $2,945 of government grants in connection with the Canada Emergency Wage Subsidy program, a new subsidy program created by the Government of Canada in 2020 in response to the COVID-19 pandemic. These grants were recorded as a reduction of salaries expense and other related charges and are recognized as follows in the consolidated statement of operations: Cost of sales and other production expenses $ 278 Research and development expenses 2,084 Administration, selling and marketing expenses 583 Total $ 2,945 Of the total subsidy recognized in 2020, $2,174 was outstanding and included in tax credits and government grants receivable at June 30, 2020.

Segmented information

Segmented information	6 Months Ended
	Jun. 30, 2020
Disclosure Of Operating Segments [Abstract]
Segmented information	14. Segmented Information The Company has two operating segments at June 30, 2020, which are namely, the small molecule therapeutics segment and the plasma-derived therapeutics segment. a) Revenues and expenses by operating segments Segment revenues are with external customers unless otherwise specified. Small Plasma- Reconciliation molecule derived to statement For the quarter ended June 30, 2020 therapeutics therapeutics of operations Total Revenues $ - $ 505 $ 35 $ 540 Expenses Cost of sales and other production expenses - 458 - 458 Manufacturing and purchase cost of product candidates used for R&D activities 10 7,465 - 7,475 R&D - Other expenses 3,494 4,778 50 8,322 Administration, selling and marketing expenses 888 1,651 7,312 9,851 Segment loss $ (4,392 ) $ (13,847 ) $ (7,327 ) $ (25,566 ) Loss on foreign exchange 539 Finance costs 1,852 Net loss from continuing operations before taxes $ (27,957 ) Other information Depreciation and amortization $ 235 $ 2,034 $ 174 $ 2,443 Share-based payment expense 414 183 1,827 2,424 Small Plasma- Reconciliation molecule derived to statement For the quarter ended June 30, 2019 therapeutics therapeutics of operations Total Revenues $ 2 $ 725 $ 35 $ 762 Expenses Cost of sales and other production expenses - 533 59 592 Manufacturing and purchase cost of product candidates used for R&D activities 20 11,888 (144 ) 11,764 R&D - Other expenses 3,853 6,631 41 10,525 Administration, selling and marketing expenses 1,608 2,056 14,381 18,045 Segment loss $ (5,479 ) $ (20,383 ) $ (14,302 ) $ (40,164 ) Loss on foreign exchange 256 Finance costs 3,348 Loss on extinguishments of liabilities 92,294 Change in fair value of financial instruments measured at fair value through profit or loss (1,369 ) Net loss from continuing operations before taxes $ (134,693 ) Other information Depreciation and amortization $ 186 $ 1,824 $ 160 $ 2,170 Share-based payment expense 3,390 3,119 8,216 14,725 For the six months ended June 30, 2020 Small molecule therapeutics Plasma- derived therapeutics Reconciliation to statement of operations Total Revenues $ - $ 1,406 $ 237 $ 1,643 Expenses Cost of sales and other production expenses - 1,104 38 1,142 Manufacturing and purchase cost of product candidates used for R&D activities 42 16,167 - 16,209 R&D - Other expenses 6,987 9,510 76 16,573 Administration, selling and marketing expenses 1,604 3,734 15,185 20,523 Segment loss $ (8,633 ) $ (29,109 ) $ (15,062 ) $ (52,804 ) Gain on foreign exchange (593 ) Finance costs 3,482 Gain on extinguishments of liabilities (79 ) Net loss from continuing operations before taxes $ (55,614 ) Other information Depreciation and amortization $ 463 $ 3,267 $ 342 $ 4,072 Share-based payment expense 972 187 3,642 4,801 For the six months ended June 30, 2019 Small molecule therapeutics Plasma- derived therapeutics Reconciliation to statement of operations Total Revenues $ 33 $ 2,930 $ 63 $ 3,026 Expenses Cost of sales and other production expenses - 1,663 59 1,722 Manufacturing and purchase cost of product candidates used for R&D activities 20 21,122 (161 ) 20,981 R&D - Other expenses 6,558 12,113 108 18,779 Administration, selling and marketing expenses 2,259 4,026 18,855 25,140 Segment loss $ (8,804 ) $ (35,994 ) $ (18,798 ) $ (63,596 ) Gain on foreign exchange (1,520 ) Finance costs 10,497 Loss on extinguishments of liabilities 92,374 Change in fair value of financial instruments measured at fair value through profit or loss (1,140 ) Net loss from continuing operations before taxes $ (163,807 ) Other information Depreciation and amortization $ 363 $ 3,623 $ 304 $ 4,290 Share-based payment expense 3,787 3,470 8,933 16,190 b) Revenues by location from continuing operations Revenues are attributed to countries based on the location of customers. Quarters ended June 30, Six months ended June 30, 2020 2019 2020 2019 United States $ 339 $ 323 $ 1,070 $ 1,745 Canada 201 439 406 1,281 United Kingdom - - 167 - $ 540 $ 762 $ 1,643 $ 3,026 The Company derives significant revenues from certain customers. For the six months ended June 30, 2020 there was one party in the plasma-derived therapeutics segment who accounted for 65% of total revenues from continuing operations. For the six months ended June 30, 2019, there were two parties in the plasma-derived therapeutics segment who accounted for 97% (58% and 39% respectively) of total revenues for continuing operations.

Related party transactions

Related party transactions	6 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
Related party transactions	15. Related party transactions During the quarter and six months ended June 30, 2020, the Company paid interest on the loan with its parent, SALP, in the amount of $252 and $503 ($850 and $3,032 for the quarter and six months ended June 30, 2019). The Company has a nonrevolving line of credit or LOC agreement with SALP, of which $29,123 is currently available to be drawn as of June 30, 2020, bearing a stated interest of 10%, payable quarterly, and maturing on April 23, 2024 of which $nil has been drawn as at June 30, 2020. The LOC limit available to draw upon has previously been, and will continue to be, automatically reduced by the amounts of net proceeds generated upon the occurrence of all or any of the following transactions: a licensing transaction for the Company’s product candidate Ryplazim ® During the quarter and six months ended June 30, 2020, the Company recorded $107 and $133 ($nil for the six months ended June 30, 2019) of research and development expenses, relating to a consulting service agreement signed with one of its directors in 2019 of which $107 remains payable as at June 30, 2020.

Subsequent events

Subsequent events	6 Months Ended
	Jun. 30, 2020
Disclosure Of Nonadjusting Events After Reporting Period [Abstract]
Subsequent events	16. Subsequent Events On July 17, 2020, the Company acquired all of the issued and outstanding shares of Fairhaven Pharmaceuticals Inc. or Fairhaven in return for the issuance of 202,308 common shares to the former shareholders of Fairhaven on the acquisition date. The fair value of the shares was $3.4 million, calculated using the closing price of the shares on July 17, 2020. Under the purchase agreement, the Company may be required to make additional payments in shares up to an aggregate value of $4.4 million, subject to the achievement of certain pre-determined research and development milestones. The number of shares to be issued for the achievement of future milestones would be calculated using a share price equal to the five-trading day volume weighted average price of the Company’s common shares prior to such milestone events being achieved. On July 17, 2020, concurrently with the acquisition of Fairhaven, the Company issued $2.4 million aggregate principal amount of secured convertible debentures or SDC to certain former Fairhaven shareholders, bearing an interest rate of 8% per annum, compounded quarterly, for the continued development of the Fairhaven R&D program. The SCD mature on March 31, 2022, the Maturity Date, unless converted into common shares of the Company prior to the Maturity Date. At any time prior to the Maturity Date, the SCD holders shall have a collective right to, and Liminal shall have the right upon certain pre-determined events to require each holder of the SCD to purchase additional SDC for an aggregate principal amount of up to $5.7 million for all the holders. The SDC may be converted into common shares of the Company, using the 5-day weighted average share price of Liminal’s common shares immediately preceding the date of conversion at the option of the Company subject to certain conditions, or at the option of the holders of the SDC at any time on, or before the Maturity Date. The Company is currently assessing the accounting treatment for these transactions.

Significant accounting polici_2

Significant accounting policies (Policies)	6 Months Ended
	Jun. 30, 2020
Significant Accounting Policies [Abstract]
Accounting framework	a) Accounting framework These unaudited condensed interim consolidated financial statements or interim financial statements for the quarter and six months ended June 30, 2020 have been prepared in accordance with IAS 34, Interim financial reporting www.sec.gov/edgar and at www.sedar.com These interim financial statements were approved for issue on August 10, 2020 by the Company’s Audit, Risk and Finance committee as delegated by the Board of Directors.
Adoption of new accounting standards	b) Adoption of new accounting standards The accounting policies used in these interim financial statements are consistent with those applied by the Company in its December 31, 2019 audited annual consolidated financial statements and no new accounting standards were adopted during the six-months ended June 30, 2020.
New standards and interpretations not yet adopted	c) New standards and interpretations not yet adopted The IFRS accounting standards, amendments, and interpretations that the Company reasonably expects may have a material impact on the disclosures, the financial position or results of operations of the Company when applied at a future date are as follows: Amendments to IAS 1, Presentation of Financial Statements , - IAS 1 has been revised to clarify how to classify debt and other liabilities as current or non-current. The amendments help to determine whether, in the statement of financial position, debt and other liabilities with an uncertain settlement date should be classified as current (due or potentially due to be settled within one year) or non-current. The amendments also include clarifying the classification requirements for debt an entity might settle by converting it into equity. The amendment becomes effective for annual reporting periods beginning on or after January 1, 2022 and earlier application is permitted. The Company is currently evaluating the impact of adopting this amendment on its consolidated financial statements. Amendment to IFRS 16 Leases or IFRS 16 has been revised to incorporate an amendment issued by the IASB in May 2020. The amendment permits lessees not to assess whether particular COVID-19-related rent concessions are lease modifications and, instead, account for those rent concessions as if they were not lease modifications. In addition, the amendment to IFRS 16 provides specific disclosure requirements regarding COVID-19-related rent concessions. The amendment becomes effective for annual reporting periods beginning on or after June 1, 2020 and earlier application is permitted. Presently, the Company has not benefited from COVID-19 related rent concessions.
Significant accounting judgements and critical accounting estimates	d) Significant accounting judgements and critical accounting estimates The preparation of the interim consolidated financial statements requires the use of judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the accompanying disclosures. The uncertainty that is often inherent in these estimates and assumptions could result in material adjustments to assets or liabilities affected in future periods. Other than as described below, the significant accounting judgments and critical accounting estimates applied by the Company, disclosed in the consolidated financial statements for the year ended December 31, 2019, remain unchanged. COVID-19 – The negative impact of the COVID-19 pandemic on the financial statements for the quarter and six months ended June 30, 2020 has been limited, however the Company is eligible to a Government of Canada salary subsidy program which it was able to claim during the second quarter of 2020 and which may provide further financial support while the program is available. Consistent within the global biopharmaceutical sector, some clinical programs may have been impacted by the shift of resources within hospitals to COVID-19 and related matters, resulting in potential delays to recruitment or site initiation on our clinical and preclinical programs, and potentially causing an adjustment of certain development timelines and activities. The partial disruption caused by COVID-19 may continue to impact the Company’s operations, workforce and overall business by delaying the progress of our research and development programs, regulatory submissions and reviews, regulatory inspections, production and plasma collection activities and business and corporate development activities. There is uncertainty as to the duration of the COVID-19 pandemic and related government restrictions, including travel bans, the impact on our workforce, and the availability of donors, health subjects and patients for the conduct of clinical trials, and the effects of the COVID-19 pandemic, including on the global economy, continue to be fluid. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these interim financial statements, the Company is not aware of any specific event or circumstance that would require it to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities, and the Company is unable to estimate the potential impact on its future business or our financial results as of the date of this filing. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Share-based compensation – To determine the fair value of stock options on a given date, the Company must determine the assumptions that will be used as inputs to the Black-Scholes option pricing model, including the assumption regarding the future volatility of the common shares of Liminal for the expected life of the stock options. The Company uses the historical volatility as a starting basis for the estimate and also considers whether there are factors that would indicate that the past volatility is not indicative of the future volatility. In making this assessment, management considers changes in Liminal’s activities and other factors such as a significant share consolidation. As the volatility is an assumption that has a significant impact on the calculated value of a stock option, the impact of this estimate can significantly impact the share-based payment expense over the vesting period of an award. On March 23, 2020, the board of directors of the Company approved a plan to seek shareholder approval to modify the exercise price of certain stock options as disclosed in note 11b. In order to determine when the expense related to this modification is recognized in the consolidated statement of operations, management evaluated the timing of notification to option holders, the timing and method of determining the exercise price and the service period. Management further considered whether the holders of the stock options had sufficient understanding of the terms and conditions of the potentially revised awards, the degree of certainty of the approval for the repricing and whether the service period for earning the rights to the awards had commenced. Management concluded that the definition of the grant date was not met but that the service period had commenced and therefore a preliminary calculation of the incremental fair value of the repricing of the awards was performed using assumptions as of March 31, 2020. On May 26, 2020, the conditions for a grant date were met and the options exercise price was revised to $15.21 and a final calculation to determine the incremental fair value of the repriced options was performed.

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
	Jun. 30, 2020
Discontinued Operations [Abstract]
Summary of Results and Cash Flows from Discontinued Operations	The results from discontinued operations for the quarter and six months ended June 30, 2019 are as follows: Quarter ended Six months ended June 30, 2019 June 30, 2019 Revenues $ 7,990 $ 13,959 Expenses Cost of sales and other production expenses 3,289 6,511 Research and development expenses 1,868 3,589 Administration, selling and marketing expenses 545 1,094 Gain on foreign exchange (149 ) (156 ) Finance costs 208 412 Net income from discontinued operations, net of tax of $nil $ 2,229 $ 2,509 The cash flows from discontinued operations for the six months ended June 30, 2020 and 2019 are presented in the following table: June 30, June 30, Six months ended 2020 2019 Cash flows from in operating activities $ - $ 1,056 Cash flows used in financing activities - (460 ) Cash flows from (used) in investing activities 388 (486 ) Net change in cash during the quarter $ 388 $ 110 Net effect of currency exchange rate on cash - (44 ) Net increase in cash generated by discontinued operations $ 388 $ 66

Accounts Receivable (Tables)

Accounts Receivable (Tables)	6 Months Ended
	Jun. 30, 2020
Trade And Other Receivables [Abstract]
Summary of Trade and Other Receivables	June 30, December 31, 2020 2019 Trade receivables $ 375 $ 44 Tax credits and government grants receivable 2,786 1,546 Sales taxes receivable 463 863 Other receivables 420 1,633 $ 4,044 $ 4,086

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2020
Classes Of Inventories [Abstract]
Summary of Inventories	June 30, December 31, 2020 2019 Raw materials $ 7,442 $ 7,175 Finished goods 256 357 $ 7,698 $ 7,532

Right-of-use Assets (Tables)

Right-of-use Assets (Tables)	6 Months Ended
	Jun. 30, 2020
Disclosure Of Quantitative Information About Rightofuse Assets [Abstract]
Summary of Quantitative Information About Right-Of-Use Assets	Production and laboratory Buildings equipment Other Total Net book value as at January 1, 2020 $ 32,246 $ 912 $ 96 $ 33,254 Lease modifications and other remeasurements (932 ) - - (932 ) Depreciation expense (1,938 ) (296 ) (30 ) (2,264 ) Effect of foreign exchange differences 80 - - 80 Net book value at June 30, 2020 $ 29,456 $ 616 $ 66 $ 30,138

Accounts Payable and Accrued _2

Accounts Payable and Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2020
Trade And Other Current Payables [Abstract]
Summary of Accounts Payable and Accrued Liabilities	June 30, 2020 December 31, 2019 Trade payables $ 8,609 $ 10,496 Wages and benefits payable 4,906 5,593 Current portion of royalty payment obligations (note 10) 3,308 3,043 Current portion of license acquisition payment obligation - 1,302 Current portion of other employee benefit liabilities (note 10) 2,495 2,374 $ 19,318 $ 22,808

Lease Liabilities (Tables)

Lease Liabilities (Tables)	6 Months Ended
	Jun. 30, 2020
Lease Liabilities [Abstract]
Summary of Lease Liabilities	The transactions affecting the lease liabilities during the six months ended June 30, 2020 were as follows: Balance at January 1, 2020 $ 38,237 Interest expense 3,153 Payments (3,919 ) Lease modification and other remeasurements (1,068 ) Effect of foreign exchange differences 850 Balance at June 30, 2020 $ 37,253 Less current portion of lease liabilities 8,545 Long-term portion of lease liabilities $ 28,708

Long-term Debt (Tables)

Long-term Debt (Tables)	6 Months Ended
	Jun. 30, 2020
Disclosure Of Detailed Information About Borrowings [Abstract]
Summary of Transactions of Long Term Debt	The transactions during the six months ended June 30, 2020 were as follows: 2020 Balance at January 1 $ 8,834 Stated and accreted interest 619 Repayment of principal (165 ) Repayment of stated interest (503 ) Balance at June 30 $ 8,785
Summary of Gain (Loss) on Extinguishment of Liabilities	Loss on extinguishment of liabilities due to April 23, 2019 loan modification Comprising the following elements: Debt to equity conversion $ 87,379 Expensing of financing fees on loan extinguishment 653 Extinguishment of previous loan (4,667 ) Recognition of modified loan 8,521 Expensing of increase in the fair value of the warrants 408 Loss on extinguishment of liabilities due to April 23, 2019 loan modification $ 92,294 Loss on extinguishment of liabilities to suppliers 80 Loss on extinguishments of liabilities $ 92,374

Other Long-Term Liabilities (Ta

Other Long-Term Liabilities (Tables)	6 Months Ended
	Jun. 30, 2020
Miscellaneous Noncurrent Liabilities [Abstract]
Summary of Other Long-Term Liabilities	June 30, December 31, 2020 2019 Royalty payment obligations $ 3,423 $ 3,148 Other employee benefit liabilities 2,581 2,554 $ 6,004 $ 5,702 Less: Current portion of royalty payment obligations (note 7) (3,308 ) (3,043 ) Current portion of other employee benefit liabilities (note 7) (2,495 ) (2,374 ) $ 201 $ 285

Share Capital and Other Equit_2

Share Capital and Other Equity Instruments (Tables)	6 Months Ended
	Jun. 30, 2020
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Schedule of Changes in Issued and Outstanding Common Share or RSU or Warrants	Changes in the issued and outstanding common shares of the Company during the six months ended June 30, 2020 and 2019 were as follows: June 30, 2020 June 30, 2019 Number Amount Number Amount Balance - beginning of period 23,313,164 $ 932,951 720,306 $ 583,117 Issued to acquire assets 96,833 1,240 4,420 1,326 Shares issued pursuant to a restricted share units plan (note 11b) 10,355 9,764 - - Shares issued pursuant to debt restructuring 15,050,312 228,915 Shares issued for cash - - 7,536,654 118,648 Shares released from escrow - - - 400 Shares issued in payment to suppliers - - 1,472 545 Balance - end of period 23,420,352 $ 943,955 23,313,164 $ 932,951
Schedule of Changes in Number of Stock Options Outstanding and Weighted Average Exercise Price	Changes in the number of stock options outstanding during the six months ended June 30, 2020 and 2019 were as follows: June 30, 2020 June 30, 2019 Weighted Weighted average average Number exercise price Number exercise price Balance - beginning of period 2,209,864 $ 38.72 21,625 $ 1,464.49 Granted 436,570 14.06 2,047,560 35.10 Forfeited (64,141 ) 24.42 (1,429 ) 1,352.79 Cancelled - - (9,094 ) 1,164.74 Expired (1,435 ) 2,433.20 (1,902 ) 1,110.29 Repriced - options before repricing (1,929,685 ) 35.14 - - Repriced - options after repricing 1,929,685 15.21 - - Balance - end of period 2,580,858 $ 18.67 2,056,760 $ 43.23
Summary of Weighted Average Inputs into Model and Resulting Grant Date Fair Values	The following Black-Scholes assumption were used: Expected dividend rate - Expected volatility of share price 93.2 % Risk-free interest rate 0.4 % Expected life in years 6.3 Weighted average grant date incremental fair value $ 1.55 The Company uses the Black-Scholes option pricing model to calculate the fair value of stock options. The weighted average inputs into the model and the resulting grant date fair values during the six months ended June 30, 2020 and 2019, except for the effect of the repricing were as follows: June 30, June 30, 2020 2019 Expected dividend rate - - Expected volatility of share price 91.7 % 45.0 % Risk-free interest rate 0.5 % 1.4 % Expected life in years 6.8 7.3 Weighted average grant date fair value $ 10.51 $ 13.43
Schedule of Stock Options Issued and Outstanding by Range of Exercise Price	At June 30, 2020, options issued and outstanding by range of exercise price are as follows: Weighted average remaining Weighted Weighted Range of Number contractual life average Number average exercise price outstanding (in years) exercise price exercisable exercise price $7.86-$11.99 171,250 9.3 $ 9.58 - $ - $14.06 436,570 9.9 14.06 - - $15.21 1,914,976 8.9 15.21 431,605 15.21 $27.00 - $3,190.00 58,062 8.6 194.23 56,741 185.78 2,580,858 9.1 $ 18.67 488,346 $ 35.03
Schedule of Total Share-Based Payments Expense	The total share-based payments expense, comprising the above-mentioned expenses for stock options and RSU, has been included in the consolidated statements of operations for the quarters and six months ended June 30, 2020 and 2019 as indicated in the following table: Quarter ended June 30, Six months ended June 30, 2020 2019 2020 2019 Cost of sales and other production expenses $ 10 $ 88 $ 17 $ 88 Research and development expenses 1,068 5,080 2,083 5,772 Administration, selling and marketing expenses 1,346 9,729 2,701 10,569 $ 2,424 $ 14,897 $ 4,801 $ 16,429
Restricted Stock Units
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Schedule of Changes in Issued and Outstanding Common Share or RSU or Warrants	Changes in the number of restricted share units or RSU outstanding during the six months ended June 30, 2020 and 2019 were as follows: June 30, June 30, 2020 2019 Balance - beginning of period 17,565 18,299 Granted - 12,564 Forfeited (24 ) (359 ) Released (10,355 ) - Paid in cash (2,948 ) (8,246 ) Cancelled - (4,249 ) Balance - end of period 4,238 18,009
Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Schedule of Changes in Issued and Outstanding Common Share or RSU or Warrants	The following table summarizes the changes in the number of warrants outstanding during the six months ended June 30, 2020 and 2019: June 30, 2020 June 30, 2019 Weighted Weighted average average Number exercise price Number exercise price Balance of warrants - beginning of period 172,735 $ 84.33 153,611 $ 1,028.35 Issued to acquire assets - - 19,402 156.36 Cancelled - loan modification - - (168,735 ) 872.51 Issued - loan modification - - 168,735 15.21 Balance of warrants - end of period 172,735 $ 84.33 173,013 $ 94.46 Balance of warrants exercisable - end of period 172,735 $ 84.33 171,013 $ 60.48
Schedule of Warrants Outstanding, Exercise Price, Expiry Rate and Overall Weighted Average Exercise Price	As at June 30, 2020, the following warrants were outstanding: Number Expiry date Exercise price 4,000 January 2023 3,000.00 168,735 April 2027 15.21 172,735 $ 84.33

Revenues from Continuing Oper_2

Revenues from Continuing Operations (Tables)	6 Months Ended
	Jun. 30, 2020
Revenue [Abstract]
Summary of Revenues from Continuing Operations	Quarters ended June 30, Six months ended June 30, 2020 2019 2020 2019 Revenues from the sale of goods $ 504 $ 728 $ 1,405 $ 2,926 Other revenues 36 34 238 100 $ 540 $ 762 $ 1,643 $ 3,026

Government Grants (Tables)

Government Grants (Tables)	6 Months Ended
	Jun. 30, 2020
Disclosure Of Government Grants [Abstract]
Summary of Government Grants	These grants were recorded as a reduction of salaries expense and other related charges and are recognized as follows in the consolidated statement of operations: Cost of sales and other production expenses $ 278 Research and development expenses 2,084 Administration, selling and marketing expenses 583 Total $ 2,945

Segmented Information (Tables)

Segmented Information (Tables)	6 Months Ended
	Jun. 30, 2020
Disclosure Of Operating Segments [Abstract]
Summary of Revenues and Expenses by Operating Segments	a) Revenues and expenses by operating segments Segment revenues are with external customers unless otherwise specified. Small Plasma- Reconciliation molecule derived to statement For the quarter ended June 30, 2020 therapeutics therapeutics of operations Total Revenues $ - $ 505 $ 35 $ 540 Expenses Cost of sales and other production expenses - 458 - 458 Manufacturing and purchase cost of product candidates used for R&D activities 10 7,465 - 7,475 R&D - Other expenses 3,494 4,778 50 8,322 Administration, selling and marketing expenses 888 1,651 7,312 9,851 Segment loss $ (4,392 ) $ (13,847 ) $ (7,327 ) $ (25,566 ) Loss on foreign exchange 539 Finance costs 1,852 Net loss from continuing operations before taxes $ (27,957 ) Other information Depreciation and amortization $ 235 $ 2,034 $ 174 $ 2,443 Share-based payment expense 414 183 1,827 2,424 Small Plasma- Reconciliation molecule derived to statement For the quarter ended June 30, 2019 therapeutics therapeutics of operations Total Revenues $ 2 $ 725 $ 35 $ 762 Expenses Cost of sales and other production expenses - 533 59 592 Manufacturing and purchase cost of product candidates used for R&D activities 20 11,888 (144 ) 11,764 R&D - Other expenses 3,853 6,631 41 10,525 Administration, selling and marketing expenses 1,608 2,056 14,381 18,045 Segment loss $ (5,479 ) $ (20,383 ) $ (14,302 ) $ (40,164 ) Loss on foreign exchange 256 Finance costs 3,348 Loss on extinguishments of liabilities 92,294 Change in fair value of financial instruments measured at fair value through profit or loss (1,369 ) Net loss from continuing operations before taxes $ (134,693 ) Other information Depreciation and amortization $ 186 $ 1,824 $ 160 $ 2,170 Share-based payment expense 3,390 3,119 8,216 14,725 For the six months ended June 30, 2020 Small molecule therapeutics Plasma- derived therapeutics Reconciliation to statement of operations Total Revenues $ - $ 1,406 $ 237 $ 1,643 Expenses Cost of sales and other production expenses - 1,104 38 1,142 Manufacturing and purchase cost of product candidates used for R&D activities 42 16,167 - 16,209 R&D - Other expenses 6,987 9,510 76 16,573 Administration, selling and marketing expenses 1,604 3,734 15,185 20,523 Segment loss $ (8,633 ) $ (29,109 ) $ (15,062 ) $ (52,804 ) Gain on foreign exchange (593 ) Finance costs 3,482 Gain on extinguishments of liabilities (79 ) Net loss from continuing operations before taxes $ (55,614 ) Other information Depreciation and amortization $ 463 $ 3,267 $ 342 $ 4,072 Share-based payment expense 972 187 3,642 4,801 For the six months ended June 30, 2019 Small molecule therapeutics Plasma- derived therapeutics Reconciliation to statement of operations Total Revenues $ 33 $ 2,930 $ 63 $ 3,026 Expenses Cost of sales and other production expenses - 1,663 59 1,722 Manufacturing and purchase cost of product candidates used for R&D activities 20 21,122 (161 ) 20,981 R&D - Other expenses 6,558 12,113 108 18,779 Administration, selling and marketing expenses 2,259 4,026 18,855 25,140 Segment loss $ (8,804 ) $ (35,994 ) $ (18,798 ) $ (63,596 ) Gain on foreign exchange (1,520 ) Finance costs 10,497 Loss on extinguishments of liabilities 92,374 Change in fair value of financial instruments measured at fair value through profit or loss (1,140 ) Net loss from continuing operations before taxes $ (163,807 ) Other information Depreciation and amortization $ 363 $ 3,623 $ 304 $ 4,290 Share-based payment expense 3,787 3,470 8,933 16,190
Summary of Revenues by Location from Continuing Operations	b) Revenues by location from continuing operations Revenues are attributed to countries based on the location of customers. Quarters ended June 30, Six months ended June 30, 2020 2019 2020 2019 United States $ 339 $ 323 $ 1,070 $ 1,745 Canada 201 439 406 1,281 United Kingdom - - 167 - $ 540 $ 762 $ 1,643 $ 3,026

Nature of Operations and Goin_2

Nature of Operations and Going Concern - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Disclosure Of Nature Of Operations And Going Concern [Abstract]
Net loss	$ 27,816	$ 133,703	$ 55,473	$ 162,537
Loss on extinguishment of liabilities				92,400
Operating cash flows			31,937	$ 46,633
Working capital	17,000		17,000		$ 63,600
Accumulated deficit	$ 1,022,163		$ 1,022,163		$ 967,051

Significant Accounting Polici_3

Significant Accounting Policies - Additional Information (Details)	May 26, 2020$ / shares
Significant Accounting Policies [Abstract]
Revised exercise price, share options granted	$ 15.21

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Details)	Nov. 25, 2019OperatingSegment
Discontinued Operations
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Number of operations sold	2

Discontinued Operations - Summa

Discontinued Operations - Summary of Results from Discontinued Operations (Details) - CAD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Revenues	$ 540	$ 762	$ 1,643	$ 3,026
Expenses
Cost of sales and other production expenses	458	592	1,142	1,722
Research and development expenses	15,797	22,289	32,782	39,760
Administration, selling and marketing expenses	9,851	18,045	20,523	25,140
Finance costs	1,852	3,348	3,482	10,497
Net loss from continuing operations before taxes	$ (27,957)	(134,693)	$ (55,614)	(163,807)
Discontinued Operations
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Revenues		7,990		13,959
Expenses
Cost of sales and other production expenses		3,289		6,511
Research and development expenses		1,868		3,589
Administration, selling and marketing expenses		545		1,094
Gain on foreign exchange		(149)		(156)
Finance costs		208		412
Net loss from continuing operations before taxes		$ 2,229		$ 2,509

Discontinued Operations - Sum_2

Discontinued Operations - Summary of Results from Discontinued Operations (Parenthetical) (Details) - CAD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Net income from discontinued operations, net of taxes	$ 0	$ 0
Discontinued Operations
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Net income from discontinued operations, net of taxes	$ 0	$ 0

Discontinued Operations - Sum_3

Discontinued Operations - Summary of Cash Flows from Discontinued Operations (Details) - CAD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Net change in cash and cash equivalents during the period	$ (36,730)	$ 73,722
Net effect of currency exchange rate on cash and cash equivalents	1,431	(109)
Discontinued Operations
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Cash flows from in operating activities		1,056
Cash flows used in financing activities		(460)
Cash flows from (used) in investing activities	388	(486)
Net change in cash and cash equivalents during the period	388	110
Net effect of currency exchange rate on cash and cash equivalents		(44)
Net increase in cash generated by discontinued operations	$ 388	$ 66

Accounts Receivable - Summary o

Accounts Receivable - Summary of Trade and Other Receivables (Details) - CAD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Trade And Other Receivables [Abstract]
Trade receivables	$ 375	$ 44
Tax credits and government grants receivable	2,786	1,546
Sales taxes receivable	463	863
Other receivables	420	1,633
Trade and other receivables	$ 4,044	$ 4,086

Inventories - Summary of Invent

Inventories - Summary of Inventories (Details) - CAD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Classes Of Inventories [Abstract]
Raw materials	$ 7,442	$ 7,175
Finished goods	256	357
Inventories	$ 7,698	$ 7,532

Inventories - Additional Inform

Inventories - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Continuing Operations
Classes Of Inventories [Line Items]
Cost of sales and other production expenses	$ 266	$ 457	$ 630	$ 1,486
Inventory write-downs	$ 175		$ 327
Discontinued Operations
Classes Of Inventories [Line Items]
Cost of sales and other production expenses		3,394		5,720
Inventory write-downs		$ 53		$ 467

Right-of-use Assets - Summary o

Right-of-use Assets - Summary of Quantitative Information About Right-Of-Use Assets (Details) - CAD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Net book value as at January 1, 2020	$ 33,254
Lease modifications and other remeasurements	(932)
Depreciation expense	(2,264)	$ (2,422)
Effect of foreign exchange differences	80
Net book value at June 30, 2020	30,138
Buildings
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Net book value as at January 1, 2020	32,246
Lease modifications and other remeasurements	(932)
Depreciation expense	(1,938)
Effect of foreign exchange differences	80
Net book value at June 30, 2020	29,456
Production and Laboratory Equipment
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Net book value as at January 1, 2020	912
Depreciation expense	(296)
Net book value at June 30, 2020	616
Other
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Net book value as at January 1, 2020	96
Depreciation expense	(30)
Net book value at June 30, 2020	$ 66

Accounts Payable and Accrued _3

Accounts Payable and Accrued Liabilities - Summary of Accounts Payable and Accrued Liabilities (Details) - CAD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Trade And Other Current Payables [Abstract]
Trade payables	$ 8,609	$ 10,496
Wages and benefits payable	4,906	5,593
Current portion of royalty payment obligations (note 10)	3,308	3,043
Current portion of license acquisition payment obligation		1,302
Current portion of other employee benefit liabilities (note 10)	2,495	2,374
Trade and other current payables	$ 19,318	$ 22,808

Accounts Payable and Accrued _4

Accounts Payable and Accrued Liabilities - Additional Information (Details) $ in Thousands	3 Months Ended
	Jun. 30, 2020CAD ($)
Trade And Other Current Payables [Abstract]
Out-of-period adjustment resulted in decrease in R&D Expense and trade payable	$ (819)

Lease Liabilities - Summary of

Lease Liabilities - Summary of Lease Liabilities (Details) - CAD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Disclosure Of Lease Liabilities [Line Items]
Current portion of lease liabilities (note 8)	$ 8,545		$ 8,545		$ 8,290
Long-term portion of lease liabilities (note 8)	28,708		28,708		$ 29,947
Lease Liabilities
Disclosure Of Lease Liabilities [Line Items]
Balance at January 1, 2020			38,237
Interest expense	1,604	$ 1,851	3,153	$ 3,639
Payments			(3,919)
Lease modification and other remeasurements			(1,068)
Effect of foreign exchange differences			850
Balance at June 30, 2020	37,253		37,253
Current portion of lease liabilities (note 8)	8,545		8,545
Long-term portion of lease liabilities (note 8)	$ 28,708		$ 28,708

Lease Liabilities - Additional

Lease Liabilities - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Lease Liabilities
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Interest expense	$ 1,604	$ 1,851	$ 3,153	$ 3,639

Long-term Debt - Summary of Tra

Long-term Debt - Summary of Transactions of Long Term Debt (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2020CAD ($)
Disclosure Of Detailed Information About Borrowings [Abstract]
Balance at January 1	$ 8,834
Stated and accreted interest	619
Repayment of principal	(165)
Repayment of stated interest	(503)
Balance at June 30	$ 8,785

Long-term Debt - Additional Inf

Long-term Debt - Additional Information (Details) $ / shares in Units, $ in Thousands, $ in Millions	Apr. 23, 2019CAD ($)$ / sharesshares	Apr. 23, 2019USD ($)	Mar. 22, 2019CAD ($)	Feb. 22, 2019USD ($)$ / shares	Jun. 30, 2020CAD ($)	Jun. 30, 2020CAD ($)	Dec. 31, 2019CAD ($)	Jun. 30, 2019CAD ($)	May 21, 2019shares	Dec. 31, 2018CAD ($)
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal/face amount					$ 10,000	$ 10,000	$ 10,000
Borrowings	$ 141,536				8,785	8,785	8,834
Common shares, issued | shares									2,592,628
Share capital					943,955	943,955	$ 932,951	$ 932,951		$ 583,117
Loss (gain) on extinguishments of liabilities					$ 92,374	$ 92,374
Fourth Loan Agreement | Tranche Nine
Disclosure Of Detailed Information About Borrowings [Line Items]
Borrowings				$ 10
Date of credit facility drawn				Feb. 22, 2019
Fourth Loan Agreement | Tranche Ten
Disclosure Of Detailed Information About Borrowings [Line Items]
Borrowings				$ 5
Date of credit facility drawn				Mar. 22, 2019
Fourth Loan Agreement | Tranche Nine and Ten
Disclosure Of Detailed Information About Borrowings [Line Items]
Credit facility, interest rate			8.50%	8.50%
Increase (decrease) in fair value of warrants			$ 1,137
Fair value of transaction costs			45
Fair value of financing fees			1,137
Drawdown on credit facility			$ 18,677
Fourth Loan Agreement | Tranche Nine and Ten | Warrants #9
Disclosure Of Detailed Information About Borrowings [Line Items]
Maximum exercise price of preferred share | $ / shares				$ 1,000
Minimum exercise price of preferred share | $ / shares				$ 156.36
Third Original Issue Discount Loan
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal/face amount	$ 10,000
Credit facility, interest rate	10.00%
Conversion price per common share | $ / shares	$ 15.21
Interest due on credit facility	$ 663
Reduction of long-term debt	$ 141,536
Common shares, issued | shares	15,050,312
Share capital	$ 228,915
Loss on extinguishment of loan	87,379
Interest due on credit facility paid in cash	$ 663
Exercise price of warrants per common share | $ / shares	$ 15.21
Warrants maturity date	April 23, 2027	April 23, 2027
Extinguishment of loans following a debt modification	$ 4,667
Recognition of loans following a debt modification	8,521
Gain (loss) on debt extinguishment	$ 3,854
Third Original Issue Discount Loan | Discounted Cash Flow
Disclosure Of Detailed Information About Borrowings [Line Items]
Credit facility, interest rate	15.10%
Third Original Issue Discount Loan | Bottom of Range
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal/face amount	$ 10,000
US Credit Facility Agreement
Disclosure Of Detailed Information About Borrowings [Line Items]
Drawdown on credit facility		$ 95
Original Issue Discount Loan Agreement | Top of Range
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal/face amount	$ 99,552
S A L P
Disclosure Of Detailed Information About Borrowings [Line Items]
Maturity date						April 23, 2024
Credit facility, interest rate					10.00%	10.00%	10.00%
Effective Interest Rate
Disclosure Of Detailed Information About Borrowings [Line Items]
Credit facility, interest rate					15.05%	15.05%	15.05%

Long-term Debt - Summary of Los

Long-term Debt - Summary of Loss on Extinguishment of Liabilities (Details) - CAD ($) $ in Thousands	Apr. 23, 2019	Jun. 30, 2020	Jun. 30, 2020
Loss on extinguishment of liabilities due to April 23, 2019 loan modification
Debt to equity conversion	$ 87,379
Loss (gain) on extinguishments of liabilities		$ 92,374	$ 92,374
Loss on extinguishment of liabilities to suppliers			80
April 23, 2019 Loan Modification
Loss on extinguishment of liabilities due to April 23, 2019 loan modification
Debt to equity conversion			87,379
Expensing of financing fees on loan extinguishment			653
Extinguishment of previous loan			(4,667)
Recognition of modified loan			8,521
Expensing of increase in the fair value of the warrants			408
Loss (gain) on extinguishments of liabilities			$ 92,294

Other Long-Term Liabilities - S

Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Details) - CAD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Miscellaneous Noncurrent Liabilities [Abstract]
Royalty payment obligations	$ 3,423	$ 3,148
Other employee benefit liabilities	2,581	2,554
Other Liabilities	6,004	5,702
Current portion of royalty payment obligations (note 7)	(3,308)	(3,043)
Current portion of other employee benefit liabilities (note 7)	(2,495)	(2,374)
Other non-current liabilities	$ 201	$ 285

Share Capital and Other Equit_3

Share Capital and Other Equity Instruments - Schedule of Changes in Issued and Outstanding Common Shares (Details) - CAD ($)	Jan. 29, 2020	Apr. 23, 2019	Feb. 27, 2019	Jan. 29, 2019	Jun. 30, 2020	Jun. 30, 2019
Disclosure Of Classes Of Share Capital [Abstract]
Balance - beginning of year, Number					23,313,164	720,306
Issued to acquire assets, Number	96,833			4,420	96,833	4,420
Shares issued pursuant to a restricted share units plan, Number					10,355
Shares issued pursuant to debt restructuring, Number		15,050,312				15,050,312
Shares issued for cash, Number						7,536,654
Shares issued in payment to suppliers, Number			1,472			1,472
Balance - end of year, Number					23,420,352	23,313,164
Balance - beginning of period					$ 932,951,000	$ 583,117,000
Issued to acquire assets				$ 1,326,000	1,240,000	1,326,000
Shares issued pursuant to a restricted share units plan					9,764,000
Shares issued pursuant to debt restructuring		$ 228,915,000				228,915,000
Shares issued for cash						118,648,000
Shares released from escrow						400,000
Shares issued in payment to suppliers	$ 1,240,000		$ 545,000			545,000
Balance - end of period					$ 943,955,000	$ 932,951,000

Share Capital and Other Equit_4

Share Capital and Other Equity Instruments - Share Capital - Additional Information (Details) $ / shares in Units, $ in Thousands, $ in Millions	Jan. 29, 2020CAD ($)shares	May 21, 2019CAD ($)$ / sharesshares	Apr. 23, 2019CAD ($)Private_Placement$ / sharesshares	Feb. 27, 2019CAD ($)shares	Jan. 29, 2019CAD ($)shares	Apr. 30, 2019CAD ($)	Nov. 30, 2018CAD ($)$ / sharesshares	Nov. 30, 2018USD ($)shares	Mar. 31, 2020CAD ($)	Jun. 30, 2020CAD ($)shares	Jun. 30, 2019CAD ($)shares	Dec. 31, 2019CAD ($)
Disclosure Of Classes Of Share Capital [Line Items]
Issued to acquire assets, Number | shares	96,833				4,420					96,833	4,420
Carrying value liabilities	$ 1,319
Shares issued in payment to suppliers	$ 1,240			$ 545							$ 545
Gain (loss) on extinguishment of liabilities				$ (80)					$ 79
Proceeds from issue of common shares		$ 39,434
Number of shares issued | shares		2,592,628
Share issue transaction costs		$ 271
Net proceeds from issue of common shares		$ 39,163
Shares issued in settlement of license acquisition payment obligation | shares	96,833				4,420					96,833	4,420
Share capital recorded from stock issuance under license acquisition payment					$ 1,326					$ 1,240	$ 1,326
Shares issued in payment to suppliers, Number | shares				1,472							1,472
Carrying value accounts payable to suppliers				$ 465
Shares issued in payment to suppliers	$ 1,240			$ 545							$ 545
Share purchase loan outstanding						$ 400
Amount held in escrow used for payment on loan extinguishment						$ 137
Shares issued pursuant to debt restructuring, Number | shares			15,050,312								15,050,312
Shares issued, at fair value | $ / shares			$ 15.21
Shares issued pursuant to debt restructuring			$ 228,915								$ 228,915
Adjustment to carrying value of loan			141,536							$ 8,785		$ 8,834
Debt to equity conversion			(87,379)
Par value per share | $ / shares		$ 15.21
Rights offering additional shares offered | shares		20
Private Placement
Disclosure Of Classes Of Share Capital [Line Items]
Proceeds from issue of common shares			$ 75,000
Number of shares issued | shares			4,931,161
Share issue transaction costs			$ 4,802
Net proceeds from issue of common shares			$ 70,197
Number of private placements closed | Private_Placement			2
Par value per share | $ / shares			$ 15.21
At-the-Market” (“ATM”) Equity Distribution Agreement
Disclosure Of Classes Of Share Capital [Line Items]
Proceeds from issue of common shares							$ 4,214
Number of shares issued | shares							12,865	12,865
Average price per share | $ / shares							$ 327.55
Share issue transaction costs							$ 248
Net proceeds from issue of common shares							$ 3,966
Top of Range | At-the-Market” (“ATM”) Equity Distribution Agreement
Disclosure Of Classes Of Share Capital [Line Items]
Proceeds from issue of common shares								$ 31

Share Capital and Other Equit_5

Share Capital and Other Equity Instruments - Schedule of Changes in Number of Stock Options Outstanding and Weighted Average Exercise Price (Details)	Jun. 08, 2020$ / shares	May 26, 2020$ / shares	Jun. 30, 2020shares$ / shares	Jun. 30, 2019shares$ / shares
Disclosure Of Classes Of Share Capital [Abstract]
Number of Share Options, Beginning Balance | shares			2,209,864	21,625
Number of Share Options, Granted | shares			436,570	2,047,560
Number of Share Options, Forfeited | shares			(64,141)	(1,429)
Number of Share Options, Cancelled | shares				(9,094)
Number of Share Options, Expired | shares			(1,435)	(1,902)
Number of options, Repriced - options before repricing | shares			(1,929,685)
Number of options, Repriced - options after repricing | shares			1,929,685
Number of share Options, Ending Balance | shares			2,580,858	2,056,760
Weighted Average Exercise Price, Beginning Balance | $ / shares			$ 38.72	$ 1,464.49
Weighted Average Exercise Price, Granted | $ / shares			14.06	35.10
Weighted Average Exercise Price, Forfeited | $ / shares			24.42	1,352.79
Weighted Average Exercise Price, Cancelled | $ / shares				1,164.74
Weighted Average Exercise Price, Expired | $ / shares			2,433.20	1,110.29
Weighted Average Exercise Price, Repriced - options before repricing | $ / shares			35.14
Weighted Average Exercise Price, Repriced - options after repricing | $ / shares	$ 36	$ 15.21	15.21
Weighted Average Exercise Price, Ending Balance | $ / shares			$ 18.67	$ 43.23

Share Capital and Other Equit_6

Share Capital and Other Equity Instruments - Contributed Surplus (Share-Based Payments) - Additional Information (Details) $ / shares in Units, $ in Thousands	Jun. 08, 2020shares$ / shares	May 26, 2020CAD ($)$ / shares	Jun. 19, 2019shares$ / shares	Jun. 04, 2019shares$ / shares	May 07, 2019shares	Jan. 31, 2019shares$ / shares	Jun. 30, 2019shares$ / shares	May 31, 2019CAD ($)shares	Jun. 30, 2020CAD ($)	Mar. 31, 2020CAD ($)shares	Jun. 30, 2019CAD ($)	Jun. 30, 2020CAD ($)shares$ / shares	Jun. 30, 2019CAD ($)shares$ / shares	Dec. 31, 2019$ / shares
Disclosure Of Classes Of Share Capital [Line Items]
Number of repricing of options outstanding	1,929,685
Weighted average exercise price of repricing options | $ / shares	$ 27	$ 15.21
Weighted Average Exercise Price, Repriced - options after repricing | $ / shares	$ 36	$ 15.21										$ 15.21
Incremental fair value of the repricing options | $		$ 3,000
Number of stock options granted												436,570	2,047,560
Exercise price of options granted | $ / shares		$ 15.21
Contractual life of outstanding share options												9 years 1 month 6 days
Number of stock options expired												1,435	1,902
Weighted average price of options, cancelled | $ / shares												$ 2,433.20	$ 1,110.29
Share-based payment compensation expense | $									$ 2,424		$ 14,897	$ 4,801	$ 16,429
Share-based payments expense (note 11b) | $												$ 4,761	$ 16,008
Weighted Average Exercise Price, Granted | $ / shares												$ 14.06	$ 35.10
2017-2019
Disclosure Of Classes Of Share Capital [Line Items]
Performance based RSU					12,886
2018-2020
Disclosure Of Classes Of Share Capital [Line Items]
Performance based RSU					12,886
Stock Options
Disclosure Of Classes Of Share Capital [Line Items]
Number of stock options granted						1,622						436,570
Exercise price of options granted | $ / shares						$ 300						$ 14.06
Vesting period			4 years									4 years
Contractual life of outstanding share options												10 years	10 years
Number of stock options vested			60,717
Number of stock options issued			251,714
Exercise price of options issued | $ / shares			$ 27
Weighted average grant date fair value of stock options issued | $ / shares														$ 13.17
Number of stock options expired							9,094
Weighted average price of options, cancelled | $ / shares							$ 1,164.74
Share-based payment compensation expense | $									2,407		6,736	$ 4,770	$ 7,224
Stock Options | Key Management
Disclosure Of Classes Of Share Capital [Line Items]
Number of stock options granted				1,794,224
Exercise price of options granted | $ / shares				$ 36
Vesting period				6 years
Number of stock options vested				248,825
RSU
Disclosure Of Classes Of Share Capital [Line Items]
Vesting period						1 year
Number RSU paid in cash								8,246		2,948		2,948	8,246
Reduction to contributed surplus | $								$ 421		$ 40
Number RSU vested								12,564				70	7,643
Number of unvested RSU outstanding												4,168	10,366
Number RSU granted						12,564							12,564
Weighted Average Exercise Price, Granted | $ / shares						$ 300
Number RSU released								8,246				10,355
Cancellation of units													4,249
Share-based payments
Disclosure Of Classes Of Share Capital [Line Items]
Share-based payments expense (note 11b) | $									$ 17		8,161	$ 31	$ 9,205
Compensation related to key management personnel | $											$ 5,668		$ 6,502
Performance-based RSU
Disclosure Of Classes Of Share Capital [Line Items]
Time vesting units achievement range					100.00%
Cancellation of units					4,305
Performance-based RSU | Bottom of Range
Disclosure Of Classes Of Share Capital [Line Items]
Outcome of Performance Conditions					0.00%
Percentage of performance based condition					0.00%
Performance-based RSU | Top of Range
Disclosure Of Classes Of Share Capital [Line Items]
Outcome of Performance Conditions					150.00%
Percentage of performance based condition					150.00%

Share Capital and Other Equit_7

Share Capital and Other Equity Instruments - Summary of Weighted Average Inputs into Model and Resulting Grant Date Fair Values (Details)	May 26, 2020yr$ / shares	Jun. 30, 2020yr$ / shares	Jun. 30, 2019yr$ / shares
Disclosure Of Classes Of Share Capital [Abstract]
Expected volatility of share price	93.20%	91.70%	45.00%
Risk-free interest rate	0.40%	0.50%	1.40%
Expected life in years | yr	6.3	6.8	7.3
Weighted average grant date incremental fair value | $ / shares	$ 1.55	$ 10.51	$ 13.43

Share Capital and Other Equit_8

Share Capital and Other Equity Instruments - Schedule of Stock Options Issued and Outstanding by Range of Exercise Price (Details)	6 Months Ended
	Jun. 30, 2020shares$ / shares	Dec. 31, 2019shares$ / shares	Jun. 30, 2019shares$ / shares	Dec. 31, 2018shares$ / shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	2,580,858	2,209,864	2,056,760	21,625
Weighted average remaining contractual life (in years)	9 years 1 month 6 days
Options outstanding, weighted average exercise price | $ / shares	$ 18.67	$ 38.72	$ 43.23	$ 1,464.49
Number exercisable, options | shares	488,346
Options exercisable, weighted average exercise price | $ / shares	$ 35.03
$7.86-$11.99
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	171,250
Weighted average remaining contractual life (in years)	9 years 3 months 18 days
Options outstanding, weighted average exercise price | $ / shares	$ 9.58
$14.06
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	436,570
Weighted average remaining contractual life (in years)	9 years 10 months 24 days
Options outstanding, weighted average exercise price | $ / shares	$ 14.06
$15.21
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	1,914,976
Weighted average remaining contractual life (in years)	8 years 10 months 24 days
Options outstanding, weighted average exercise price | $ / shares	$ 15.21
Number exercisable, options | shares	431,605
Options exercisable, weighted average exercise price | $ / shares	$ 15.21
$27.00 - $3,190.00
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	58,062
Weighted average remaining contractual life (in years)	8 years 7 months 6 days
Options outstanding, weighted average exercise price | $ / shares	$ 194.23
Number exercisable, options | shares	56,741
Options exercisable, weighted average exercise price | $ / shares	$ 185.78

Share Capital and Other Equit_9

Share Capital and Other Equity Instruments - Schedule of Stock Options Issued and Outstanding by Range of Exercise Price (Parenthetical) (Details)	Jun. 30, 2020$ / shares
$7.86-$11.99 | Bottom of Range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	$ 7.86
$7.86-$11.99 | Top of Range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	11.99
$14.06
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	14.06
$15.21
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	15.21
$27.00 - $3,190.00 | Bottom of Range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	27
$27.00 - $3,190.00 | Top of Range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	$ 3,190

Share Capital and Other Equi_10

Share Capital and Other Equity Instruments - Schedule of Changes in Number of RSU outstanding (Details) - RSU	Jan. 31, 2019shares	May 31, 2019shares	Mar. 31, 2020shares	Jun. 30, 2020shares	Jun. 30, 2019shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Balance - beginning of period			17,565	17,565	18,299
Granted	12,564				12,564
Forfeited				(24)	(359)
Released		(8,246)		(10,355)
Paid in cash		(8,246)	(2,948)	(2,948)	(8,246)
Cancelled					(4,249)
Balance - end of period				4,238	18,009

Share Capital and Other Equi_11

Share Capital and Other Equity Instruments - Schedule of Total Share-Based Payments Expense (Details) - CAD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based payments expense	$ 2,424	$ 14,897	$ 4,801	$ 16,429
Cost of Sales and Other Production Expenses
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based payments expense	10	88	17	88
Research and Development Expenses
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based payments expense	1,068	5,080	2,083	5,772
Administration, Selling and Marketing Expenses
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based payments expense	$ 1,346	$ 9,729	$ 2,701	$ 10,569

Share Capital and Other Equi_12

Share Capital and Other Equity Instruments - Summary of Changes in Number of Warrants Outstanding and Weighted Average Exercise Price (Details)	6 Months Ended
	Jun. 30, 2019Warrant$ / shares	Jun. 30, 2020Warrant$ / shares
Disclosure Of Classes Of Share Capital [Abstract]
Number of warrants, beginning of period | Warrant	153,611
Number of warrants, Issued to acquire assets | Warrant	19,402
Number of warrants, Cancelled - loan modification | Warrant	(168,735)
Number of warrants, Issued - loan modification | Warrant	168,735
Number of warrants, ending of period | Warrant	173,013
Number of warrants, exercisable - end of period | Warrant	171,013	172,735
Weighted average exercise price, beginning of period | $ / shares	$ 1,028.35
Weighted average exercise price, Issued to acquire assets | $ / shares	156.36
Weighted average exercise price, Cancelled - loan modification | $ / shares	872.51
Weighted average exercise price, Issued - loan modification | $ / shares	15.21
Weighted average exercise price, beginning of period | $ / shares	94.46
Weighted average exercise price, exercisable - end of period | $ / shares	$ 60.48	$ 84.33

Share Capital and Other Equi_13

Share Capital and Other Equity Instruments - Warrants - Additional Information (Details) - Warrants #9 - CAD ($) $ / shares in Units, $ in Thousands	Feb. 22, 2019	Jun. 30, 2020
Disclosure Of Classes Of Share Capital [Line Items]
Number of warrants issued	19,402
Range of exercise price	$ 156.36
Increase decrease in fair value of replacement warrant compared to cancelled warrant		$ 229

Share Capital and Other Equi_14

Share Capital and Other Equity Instruments - Schedule of Warrants Outstanding, Exercise Price, Expiry Rate and Overall Weighted Average Exercise Price (Details)	6 Months Ended
	Jun. 30, 2020Warrant$ / shares	Dec. 31, 2019Warrant$ / shares	Jun. 30, 2019Warrant$ / shares	Dec. 31, 2018Warrant$ / shares
Disclosure Of Classes Of Share Capital [Line Items]
Number | Warrant	172,735	172,735	173,013	153,611
Exercise price of warrant | $ / shares	$ 84.33	$ 84.33	$ 94.46	$ 1,028.35
Warrant Expires on January 2023
Disclosure Of Classes Of Share Capital [Line Items]
Number | Warrant	4,000
Expiry date	Jan. 31, 2023
Exercise price of warrant | $ / shares	$ 3,000
Warrant Expires on April 2027
Disclosure Of Classes Of Share Capital [Line Items]
Number | Warrant	168,735
Expiry date	Apr. 30, 2027
Exercise price of warrant | $ / shares	$ 15.21

Revenues from Continuing Oper_3

Revenues from Continuing Operations - Summary of Revenues from Continuing Operations (Details) - CAD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue [Abstract]
Revenues from the sale of goods	$ 504	$ 728	$ 1,405	$ 2,926
Other revenues	36	34	238	100
Revenues from continuing operations	$ 540	$ 762	$ 1,643	$ 3,026

Government Grants - Additional

Government Grants - Additional Information (Details) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020CAD ($)	Jun. 30, 2020CAD ($)
Disclosure Of Government Grants [Abstract]
Government grants recognized	$ 2,945	$ 2,945
Government grants outstanding and included in tax credits and government grants receivable	$ 2,174	$ 2,174

Government Grants - Summary of

Government Grants - Summary of Government Grants (Details) - CAD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
Disclosure Of Government Grants [Line Items]
Government grants recognized	$ 2,945	$ 2,945
Cost of Sales and Other Production Expenses
Disclosure Of Government Grants [Line Items]
Government grants recognized		278
Research and Development Expenses
Disclosure Of Government Grants [Line Items]
Government grants recognized		2,084
Administration, Selling and Marketing Expenses
Disclosure Of Government Grants [Line Items]
Government grants recognized		$ 583

Segmented Information - Additio

Segmented Information - Additional Information (Details)	6 Months Ended
	Jun. 30, 2020OperatingSegmentCustomer	Jun. 30, 2019Customer
Disclosure Of Operating Segments [Line Items]
Number of operating segments | OperatingSegment	2
Plasma Derived Therapeutics
Disclosure Of Operating Segments [Line Items]
Number of customers derives revenues | Customer	1	2
Percentage of revenue from continuing operations	65.00%	97.00%
Plasma Derived Therapeutics | Customer One
Disclosure Of Operating Segments [Line Items]
Percentage of revenue from continuing operations		58.00%
Plasma Derived Therapeutics | Customer Two
Disclosure Of Operating Segments [Line Items]
Percentage of revenue from continuing operations		39.00%

Segmented Information - Summary

Segmented Information - Summary of Revenues and Expenses by Operating Segments (Details) - CAD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disclosure Of Operating Segments [Line Items]
Revenues	$ 540	$ 762	$ 1,643	$ 3,026
Expenses
Cost of sales and other production expenses	458	592	1,142	1,722
Manufacturing and purchase cost of product candidates used for R&D activities	7,475	11,764	16,209	20,981
R&D - Other expenses	8,322	10,525	16,573	18,779
Administration, selling and marketing expenses	9,851	18,045	20,523	25,140
Segment loss	(25,566)	(40,164)	(52,804)	(63,596)
Loss (gain) on foreign exchange	539	256	(593)	(1,520)
Finance costs	1,852	3,348	3,482	10,497
Loss (gain) on extinguishments of liabilities		92,294	(79)	92,374
Change in fair value of financial instruments measured at fair value through profit or loss		(1,369)		(1,140)
Net income (loss) from continuing operations before taxes	(27,957)	(134,693)	(55,614)	(163,807)
Net loss from continuing operations before taxes	(27,957)	(134,693)	(55,614)	(163,807)
Other information
Depreciation and amortization	2,443	2,170	4,072	4,290
Share-based payment expense	2,424	14,725	4,801	16,190
Operating Segments | Small Molecule Therapeutics
Disclosure Of Operating Segments [Line Items]
Revenues		2		33
Expenses
Manufacturing and purchase cost of product candidates used for R&D activities	10	20	42	20
R&D - Other expenses	3,494	3,853	6,987	6,558
Administration, selling and marketing expenses	888	1,608	1,604	2,259
Segment loss	(4,392)	(5,479)	(8,633)	(8,804)
Other information
Depreciation and amortization	235	186	463	363
Share-based payment expense	414	3,390	972	3,787
Operating Segments | Plasma Derived Therapeutics
Disclosure Of Operating Segments [Line Items]
Revenues	505	725	1,406	2,930
Expenses
Cost of sales and other production expenses	458	533	1,104	1,663
Manufacturing and purchase cost of product candidates used for R&D activities	7,465	11,888	16,167	21,122
R&D - Other expenses	4,778	6,631	9,510	12,113
Administration, selling and marketing expenses	1,651	2,056	3,734	4,026
Segment loss	(13,847)	(20,383)	(29,109)	(35,994)
Other information
Depreciation and amortization	2,034	1,824	3,267	3,623
Share-based payment expense	183	3,119	187	3,470
Reconciliation to Statement of Operations
Disclosure Of Operating Segments [Line Items]
Revenues	35	35	237	63
Expenses
Cost of sales and other production expenses		59	38	59
Manufacturing and purchase cost of product candidates used for R&D activities		(144)		(161)
R&D - Other expenses	50	41	76	108
Administration, selling and marketing expenses	7,312	14,381	15,185	18,855
Segment loss	(7,327)	(14,302)	(15,062)	(18,798)
Other information
Depreciation and amortization	174	160	342	304
Share-based payment expense	$ 1,827	$ 8,216	$ 3,642	$ 8,933

Segmented Information - Summa_2

Segmented Information - Summary of Revenues by Location From Continuing Operations (Details) - CAD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disclosure Of Geographical Areas [Line Items]
Revenues	$ 540	$ 762	$ 1,643	$ 3,026
United States
Disclosure Of Geographical Areas [Line Items]
Revenues	339	323	1,070	1,745
Canada
Disclosure Of Geographical Areas [Line Items]
Revenues	$ 201	$ 439	406	$ 1,281
United Kingdom
Disclosure Of Geographical Areas [Line Items]
Revenues			$ 167

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - CAD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Related Party Transactions [Line Items]
Interest paid on loan			$ 503,000	$ 3,032,000
Research and development expenses	$ 15,797,000	$ 22,289,000	32,782,000	39,760,000
S A L P
Related Party Transactions [Line Items]
Interest paid on loan	$ 252,000	$ 850,000	$ 503,000	$ 3,032,000
Credit facility, interest rate	10.00%		10.00%		10.00%
Maturity date			April 23, 2024
S A L P | Non-Revolving Line of Credit
Related Party Transactions [Line Items]
Maximum non-revolving credit facility	$ 29,123,000		$ 29,123,000
Credit facility, interest rate	10.00%		10.00%
Proceeds from non-revolving credit facility			$ 0
Maturity date			April 23, 2024
Consulting Service Agreement | Director
Related Party Transactions [Line Items]
Research and development expenses	$ 107,000		$ 133,000
Research and development expense payable	$ 107,000		$ 107,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - Fairhaven Pharmaceuticals Inc - Events After Reporting Period $ in Millions	6 Months Ended
	Jun. 30, 2020	Jul. 17, 2020CAD ($)shares
Secured Convertible Debentures
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Aggregate principal amount of secured convertible debentures		$ 2.4
Interest rate of secured convertible debentures		8.00%
Maturity date	March 31, 2022
Aggregate principal amount of purchase additional debentures		$ 5.7
Common Shares
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
shares issued for acquisition | shares		202,308
Fair value of common shares		$ 3.4
Aggregate value of additional payment in shares		$ 4.4